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A New Pathway Responsible For 53BP1 Loss in Breast Cancer and Laminopathies 
by 
David Grotsky 
Doctor of Philosophy in Molecular Genetics and Genomics 
Washington University in St. Louis, 2012 
Susana Gonzalo, Chairperson 
 
 53BP1 is a tumor suppressor protein that is important in the non-homologous end joining 
(NHEJ) pathway for DNA double strand break repair. Mice lacking 53BP1 present with 
increased radiosensitivity and genomic instability and are cancer prone. Loss of 53BP1 has been 
implicated by our laboratory in causing genomic instability in cells that lack A-type lamins and 
work by others has shown that loss of 53BP1 is associated with breast cancers of the poorest 
prognosis - BRCA1-mutated and Triple Negative Breast Cancers (TNBC) - and contributes to 
their resistance to current therapies, such as PARP inhibitors (PARPi). Work in our laboratory 
had previously identified a novel mechanism for regulation of 53BP1 protein levels - degradation 
by the cysteine protease cathepsin L (CTSL). The main questions addressed in this dissertation 
are whether CTSL-mediated degradation of 53BP1 is a mechanism contributing to BRCA1-
mutated and TNBC tumor progression and resistance to therapy and if activation of this pathway 
is responsible for genomic instability in progeria and other laminopathies. 
 We found that CTSL-mediated degradation of 53BP1 is activated upon loss of BRCA1, 
rescuing homologous recombination (HR) and proliferation defects. Inhibiting CTSL using 
CTSL inhibitors or vitamin D treatment stabilizes levels of 53BP1 protein, leading to an increase 
xi 
 
in NHEJ and defects in HR. Stabilization of 53BP1 using CTSL inhibitors or vitamin D leads to 
increased genomic instability and compromises proliferation following ionizing radiation or 
treatment with PARPi, which could represent a novel therapeutic strategy for breast cancers with 
the poorest prognosis. Furthermore, we identified nuclear CTSL as a novel biomarker for TNBC, 
which correlated inversely with 53BP1. We also identified the signature of low nuclear vitamin 
D receptor (VDR) with low 53BP1 and high nuclear CTSL in TNBC and BRCA1-mutated 
tumors, revealing a novel triple biomarker for stratification of patients with these cancers. We 
hypothesize that these patients can be treated with vitamin D or cathepsin inhibitors to stabilize 
53BP1 levels to render tumor cells susceptible to PARPi treatment or other DNA damaging 
strategies. 
 We also show that the Δexon9Lmna mouse model of progeria exhibits telomere 
shortening and defects of heterochromatin, but not an increase in telomere deletions or an 
increase in genomic instability as seen upon loss of A-type lamins. Interestingly, the levels of 
53BP1 are maintained in cells from these mice. These results demonstrate that different lamins 
mutations present with varying phenotypes and that 53BP1 status could be an important 
determinant for maintenance of genomic instability in some lamins-related diseases. 
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CHAPTER ONE 
 
Introduction 
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1.1 Early events in the DNA damage response pathway 
Proper repair of DNA damage is essential for the maintenance of genomic stability. 
Improper or inefficient repair of DNA damage can lead to mutations, chromosomal 
translocations, or loss of genetic information that could ultimately lead to diseases, such as 
cancer (Jackson & Bartek, 2009). DNA double strand breaks are particularly dangerous to the 
cell and constantly arise from both endogenous and exogenous damaging agents (Wyman & 
Kanaar, 2006). The cell has evolved a complex pathway, the DNA damage response, to sense, 
signal, and ultimately repair double strand breaks (Figure 1-1). The current model suggests the 
MRN complex, made up of MRE11, RAD50, and NBS1, senses the DNA double strand break 
and recruits ATM to the site (Lee & Paull, 2004, 2005). ATM is a master regulator that is either 
activated by the MRN complex or autophosphorylated on S1981 resulting in its activation 
(Bakkenist & Kastan, 2003; So, Davis, & Chen, 2009). ATM then phosphorylates H2AX, a 
histone H2A variant, on S139 (Burma, Chen, Murphy, Kurimasa, & Chen, 2001; Fernandez-
Capetillo et al., 2002) which helps with the recruitment and foci formation of various DNA 
repair factors including 53BP1, NBS1, BRCA1, and MDC1 (Fernandez-Capetillo et al., 2002; 
Fernandez-Capetillo, Lee, Nussenzweig, & Nussenzweig, n.d.; Paull et al., n.d.; Stewart, Wang, 
Bignell, Taylor, & Elledge, 2003). MDC1 is considered to be a master organizer for protein 
assembly at breaks and binds directly to γH2AX to protect it from dephosphorylation (Stewart et 
al., 2003; Stucki et al., 2005). MDC1 then directly interacts with NBS1, one of the components 
of the MRN complex (Lukas et al., 2004), to promote recruitment of the ubiquitin ligase RNF8 
(Kolas et al., 2007; Mailand et al., 2007). RNF8 ubiquitylates histones H2A and H2AX leading 
to chromatin restructuring and recruitment of another ubiquitin ligase, RNF168 (Doil et al., 
2009). The ubiquitylated histones serve as marks for recruitment of the downstream effectors of 
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DNA double strand break repair, BRCA1, which facilitates homologous recombination, and 
53BP1, which facilitates non-homologous end joining (Doil et al., 2009; Kolas et al., 2007; 
Mailand et al., 2007; Stewart et al., 2009).   
 
The interaction of BRCA1 with RAP80, which contains a tandem ubiquitin-interacting motif, 
leads to BRCA1’s direct binding to ubiquitylated histones at break sites (Kim, Chen, & Yu, 
2007; Sobhian et al., 2007; B. Wang et al., 2007; Yan et al., 2007). 53BP1’s tandem tudor 
4 
 
domains have been shown to interact with dimethylated histone H4 at lysine 20 to assist with its 
recruitment (Botuyan et al., 2006), providing further evidence that chromatin status is important 
in DNA repair. Also, 53BP1 and BRCA1 are both targets of sumoylation and the SUMO E3 
ligases PIAS2 and PIAS4 are required for their recruitment to breaks (Galanty et al., 2009; 
Morris et al., 2009). Altogether, the DNA damage response is a multifaceted pathway that 
mobilizes and recruits a whole variety of nuclear factors to sites of DNA damage. This 
dissertation focuses specifically in the functional interplay of 53BP1 and BRCA1, two DNA 
repair factors with key roles in the choice of mechanism of DNA double strand break repair: 
homologous recombination or non-homologous end joining. 
1.2 Homologous recombination 
Homologous recombination (HR) is a key pathway in cells to repair DNA double strand 
breaks and is also important during meiosis. DNA repair by HR is mostly error free, and relies 
on the presence of a sister chromatid to serve as a template for recombination. Therefore, HR can 
only take place during the S/G2 phases of the cell cycle following replication of DNA. 
A key initial step in HR is double strand break end resection to create long filaments of 
single stranded DNA. In yeast, the current view is that the nuclease Sae2 (as well as nucleases 
Exo1 and Dna2) is recruited to the break by the MRE11 subunit of the MRX (MRN in 
mammals) complex to conduct the resection (Huertas, Cortés-Ledesma, Sartori, Aguilera, & 
Jackson, 2008; Mimitou & Symington, 2009). Experiments have also shown that the human 
homolog of Sae2, CtIP, is required for end resection (Sartori et al., 2007). 
Replication protein A (RPA) then binds to single stranded DNA to protect it from 
nucleases and hairpin formation (Fanning, Klimovich, & Nager, 2006). Next, RPA interacts with 
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the RAD51 recombinase followed by RAD51 displacement of RPA to form a RAD51-single 
stranded DNA coated filament (Golub, Gupta, Haaf, Wold, & Radding, 1998). In yeast, RAD51 
associates with RPA to mediate RAD51 loading on RPA-coated DNA (Song & Sung, 2000) 
while in mammals there is evidence that BRCA2 assists with RAD51 recruitment to the single 
stranded DNA-double stranded DNA junction (H. Yang, Li, Fan, Holloman, & Pavletich, 2005). 
The RAD51 coated filament then performs homology search and strand invasion, followed by 
generation of a displacement loop (D-loop) to begin the synthesis of new DNA (Heyer, Ehmsen, 
& Liu, 2010; San Filippo, Sung, & Klein, 2008). The crossing over between homologous 
chromosomes to copy DNA ensures repair with high fidelity. 
1.3 Breast cancer type 1 susceptibility protein (BRCA1) 
BRCA1 is a tumor suppressor whose mutation of one allele in the germ line results in 
susceptibility to hereditary breast and ovarian cancer (HBOC) syndrome. This syndrome is 
associated with early onset breast cancer as well as a greater risk of pancreatic, stomach, 
laryngeal, fallopian tube, and ovarian cancer. BRCA1 mutations account for approximately 5% 
of all breast cancer cases and have a lifetime risk of breast cancer of 50-80% and ovarian cancer 
of 30-50% (Roy, Chun, & Powell, 2012).  
The BRCA1 gene encodes a protein of 1863 amino acids and contains 24 exons (Miki et 
al., 1994), with a  majority of amino acids being coded by exon 11. BRCA1 contains two 
functional domains: a tandem BRCT domain at the C-terminus and a Ring domain at the N-
terminus. The Ring domain of BRCA1 has E3 ubiquitin ligase activity and can ubiquitylate other 
proteins (Panier & Durocher, 2009). BRCA1 normally forms a heterodimer with another protein 
containing BRCT and Ring domains, BARD1, which contributes to BRCA1’s stability (Joukov, 
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Chen, Fox, Green, & Livingston, 2001). BRCA1 has been attributed to a whole host of cellular 
processes including maintenance of heterochromatin, regulation of epigenetic mechanisms such 
as DNA methylation, transcriptional regulation of several genes, control of centrosome numbers, 
and miRNA biogenesis (Kawai & Amano, 2012; Mullan, Quinn, & Harkin, 2006; Shukla et al., 
2010; X. Xu et al., 1999; Zhu et al., 2011). However, BRCA1’s most characterized role has been 
in its involvement in the DNA repair pathway. BRCA1 forms foci and localizes to sites of DNA 
double strand breaks (Scully et al., 1997) and loss of BRCA1 function leads to profound 
genomic instability characterized by unrepaired DNA breaks and complex chromosomal 
aberrations and rearrangements that compromise cell viability (Tirkkonen et al., 1997; X. Xu et 
al., 1999). As such, mouse strains with exon 11 of BRCA1 deleted are embryonic lethal (Evers & 
Jonkers, 2006), however, the lethality can be rescued by loss of ATM, Chk2,  or p53, and these 
mice ultimately develop tumors (Cao et al., 2006) 
BRCA1 is recruited to DNA double strand breaks through interaction of its BRCT 
repeats with a complex consisting of Abraxis and RAP80 (Kim et al., 2007; B. Wang et al., 
2007). BRCA1 is thought to aid HR by facilitating end resection through its interaction with CtIP 
and the MRN complex, which in turn attributes a role for BRCA1 in DNA repair pathway choice 
(Chen, Nievera, Lee, & Wu, 2008; Yu, Wu, Bowcock, Aronheim, & Baer, 1998; Yun & Hiom, 
2009). BRCA1, through its association with PALB2 and BRCA2 also plays an important role in 
RAD51 recruitment to single stranded DNA (Roy et al., 2012; F. Zhang et al., 2009). 
BRCA1 is also involved in the activation of the G1/S, S-phase, and G2/M checkpoints. 
The BRCA1-BARD1 complex is required for ATM/ATR dependent phosphorylation of p53 at 
ser-15 following DNA damage (Fabbro et al., 2004). This BRCA1 dependent phosphorylation of 
p53 induces the CDK inhibitor p21 to promote the G1/S checkpoint following damage. Studies 
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have shown that the BRCA1-deficient cell line, HCC1937, has a defective S-phase checkpoint 
and reconstitution of BRCA1 in these cells restores this checkpoint (B. Xu, Kim St, & Kastan, 
2001). BRCA1 has also been shown to regulate the G2/M checkpoint by activating Chk1 kinase 
following DNA damage (Yarden, Pardo-Reoyo, Sgagias, Cowan, & Brody, 2002). BRCA1 is 
clearly essential for DNA repair and many other cellular processes. Investigating the regulation 
and functions of BRCA1 and its interactions is important for understanding its role in the cell 
and how it contributes to tumorigenesis. 
1.4 Non-homologous end joining 
 Non-homologous end joining (NHEJ) repairs DNA double strand breaks by ligation of 
two broken ends and is the dominant mechanism of DNA repair during G0, G1, and early S 
phases of the cell cycle (Lieber, Ma, Pannicke, & Schwarz, 2003). NHEJ also continues to repair 
breaks during late S and G2 phases when HR is occurring. Since no homologous chromosome is 
present as a repair template and broken ends are processed in NHEJ, it is considered to be error 
prone. Upon recognition of a double strand break, a heterodimeric complex of Ku70 and Ku80 
binds to both ends of the broken DNA which promotes end alignment of the two ends (Walker, 
Corpina, & Goldberg, 2001). The Ku complex then recruits DNA-PKCS, a member of the PIKKs 
(phosphoinositide 3-kinase-like family of protein kinases), and it is phosphorylated leading to 
inward movement of the DNA ends which allows two DNA-PKCS molecules to form a synapse 
between the broken DNA ends (DeFazio, Stansel, Griffith, & Chu, 2002; Gottlieb & Jackson, 
1993; Hartlerode & Scully, 2009). 
 Minimal end processing is required to prepare broken DNA strands for ligation. Artemis 
interacts with DNA-PKcs to form 5’-phosphorylated ligatable ends that are required for repair 
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and is also able to cleave DNA loops, flaps, and gaps (Ma, Pannicke, Schwarz, & Lieber, 2002; 
Ma, Schwarz, & Lieber, 2005; Moshous et al., 2001). Other DNA gaps generated upon DNA 
damage are likely filled in by members of the DNA polymerase X family of polymerases, 
polymerase µ, polymerase λ, and terminal deoxyribonucleotidyltransferase (TdT) (Stephanie A 
Nick McElhinny & Ramsden, 2004; Walker et al., 2001). Ligation is carried out by a complex 
consisting of the ligase, DNA ligase IV, XRCC4, which forms a scaffold by interacting with Ku 
and DNA, and XLF, which is important for stimulating ligase activity (Grawunder et al., 1997; 
Grawunder, Zimmer, & Leiber, 1998; Gu, Lu, Tsai, Schwarz, & Lieber, 2007; S A Nick 
McElhinny, Snowden, McCarville, & Ramsden, 2000). Mice lacking Artemis or DNA-PKcs are 
highly sensitive to ionizing radiation and present with immunodeficiency syndromes (Moshous 
et al., 2001; Rooney et al., 2002). 
 The core members of the NHEJ pathway are not only used to repair exogenous DNA 
damage but also for the deliberate formation and repair of DNA double strand breaks during 
class switch recombination and V(D)J (Variable, Diversity, and Joining) recombination (Dudley, 
Chaudhuri, Bassing, & Alt, 2005). NHEJ is also responsible for end joining of dysfunctional 
telomeres (Difilippantonio et al., 2008; Riha, Heacock, & Shippen, 2006), and paradoxically, Ku 
and DNA-PKcs play roles in normal telomere length maintenance (Boulton & Jackson, 1998; 
Espejel et al., 2004). Thus, classical NHEJ is important for many cellular functions. 
 In addition to this classical form of NHEJ, new evidence is emerging about a pathway 
known as alternative or backup NHEJ (A-NHEJ or B-NHEJ) where end joining can occur in the 
absence of Ku, XRCC4, or DNA ligase IV. This pathway relies on microhomology-mediated 
end-joining, where CtIP resects DNA to reveal short regions of homology which are ligated 
primarily by DNA ligase III (Bennardo, Cheng, Huang, & Stark, 2008; Simsek et al., 2011; Y. 
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Zhang & Jasin, 2011). Since resected DNA in alternative NHEJ is not repaired with sequence 
from a homologous chromosome, A-NHEJ could be a more error prone pathway than classical 
NHEJ or HR. As such, it has been shown that A-NHEJ plays a major role in formation of 
chromosomal translocations in mouse embryonic stem cells (Y. Zhang & Jasin, 2011). 
1.5 p53 Binding Protein 1 (53BP1) 
 53BP1 was originally discovered in a yeast two-hybrid screen looking for p53-interacting 
proteins (Iwabuchi, Bartel, Li, Marraccino, & Fields, 1994). Since 53BP1 contains tandem 
BRCT domains, it was associated with the DNA damage response pathway (Li & Zou, 2005). 
53BP1 has no enzymatic function and is thought to serve as a platform for recruitment of other 
DNA damage response proteins. 53BP1 is rapidly recruited to ionizing radiation induced foci 
(IRIF) following double strand break induction, colocalizes with γH2AX and is a substrate for 
ATM (Anderson, Henderson, & Adachi, 2001; Rappold, Iwabuchi, Date, & Chen, 2001; Schultz, 
Chehab, Malikzay, & Halazonetis, 2000; Ward, Minn, van Deursen, & Chen, 2003). While 
53BP1 does not appear to be necessary for core NHEJ, it is thought to be required for ATM-
dependent NHEJ following DNA damage at heterochromatin, along with H2AX, NBS1, and 
MRE11 (FitzGerald, Grenon, & Lowndes, 2009; Goodarzi et al., 2008; Riballo et al., 2004). 
Cells deficient in 53BP1 are sensitive to irradiation and have a defect in the G2/M checkpoint 
following low doses of ionizing radiation, though not high doses (Fernandez-Capetillo et al., 
2002; Nakamura et al., 2006). 53BP1 knockout mice exhibit radiosensitivity, growth retardation, 
cell cycle defects, chromosomal instability, and are cancer prone (Ward et al., 2003). 
53BP1 has established roles in NHEJ during long range DNA double strand break repair, 
such as long range V(D)J recombination and class switch recombination. NHEJ plays a major 
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role in maturation of B and T lymphocytes by generating antigen response elements through 
breaking of DNA by the RAG1 and RAG2 endonucleases and rejoining by NHEJ proteins (Noon 
& Goodarzi, 2011). 53BP1 was found to have an essential role in the joining of distal ends of the 
V(D)J genes (Difilippantonio et al., 2008). As such, 53BP1 knockout mice exhibit growth 
retardation and immune deficiencies characterized by reduction in thymus size and reduced T 
cell count (Morales et al., 2003). 53BP1 acts similarly in class switch recombination during B 
cell activation to move and join distal ends of DNA (Bothmer et al., 2011).  
The NHEJ pathway is activated in response to deprotected telomeres, which are 
recognized as DNA double strand breaks. 53BP1 was found to be important for the mobility and 
joining of telomeres upon disruption of the shelterin complex (Dimitrova, Chen, Spector, & de 
Lange, 2008). Studies in our laboratory have also implicated 53BP1 in end joining of 
dysfunctional telomeres (Gonzalez-Suarez et al., 2009). 
1.6 53BP1 and BRCA1 compete for DNA double strand break repair pathway 
choice 
 Although HR can only take place during the late S and G2 phases of the cell cycle, and 
NHEJ predominantly takes place during G0/G1 and early S phases of the cell cycle, NHEJ still 
occurs during late S and G2 phases to repair double strand breaks formed during replication. A 
key question in the DNA repair field has been how are double strand breaks directed to repair by 
error free HR rather than error prone NHEJ. A study in 2009 suggested that phosphorylation of 
the end resection protein CtIP as cells enter S phase, along with the recruitment of BRCA1 
serves as a switch to shift cells from NHEJ to HR (Yun & Hiom, 2009). This notion was 
supported by the finding that 53BP1 is able to inhibit HR by blocking end resection at double 
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strand breaks (Bothmer et al., 2011; Bunting et al., 2010). In concert with these findings, several 
studies have revealed that loss of 53BP1 rescues the embryonic lethality observed in mice with 
BRCA1 deleted of exon 11 without increasing tumorigenesis (Bouwman et al., 2010; Bunting et 
al., 2010; Cao et al., 2009).  Loss of 53BP1 rescued HR, thereby alleviating the genomic 
instability and increased tumorigenesis normally observed in these mice. The current model 
suggests that when BRCA1 is absent, 53BP1 accumulates at DNA double strand breaks and 
blocks end resection, leading to aberrantly upregulated NHEJ and chromosomal instability that 
results in proliferation arrest or cell death (Figure 1-2). When 53BP1 is lost in this context, end 
resection is allowed and HR is rescued, promoting error free DNA repair. Interestingly, 
downregulation of 53BP1 was observed in human BRCA1-mutated and triple-negative breast 
tumors (tumors with very poor prognosis that are often BRCA1-deficient) which could explain 
how these tumors overcome the genomic instability caused by HR defects (Bouwman et al., 
2010). These results have very important implications for treatment of breast cancer. 
 HR deficient cells, such as BRCA1-mutated, are exquisitely sensitive to treatment with 
poly(ADP-ribose) polymerase inhibitors (PARPi) (Bryant et al., 2005; Farmer et al., 2005). 
PARP functions as a mediator in the base excision repair pathway, which is important for the 
repair of DNA single strand breaks and gaps (McCabe et al., 2006). If PARP is inhibited, single 
strand breaks are converted to double strand breaks which are repaired primarily by HR. 
Therefore, in HR deficient cells, double strand breaks generated after PARP inhibition are not 
properly repaired leading to genomic instability and cell death. These drugs are currently being 
used in clinical trials for BRCA1-mutated breast and ovarian cancers (Fong et al., 2009). 
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However, several studies have indicated that BRCA1 mutant cells can become resistant to 
PARPi by acquiring mutations in the BRCA1 gene that restores HR (Ashworth, 2008; Swisher et 
al., 2008; W. Wang & Figg, 2008). It was also shown that loss of 53BP1 in BRCA1-deficient 
cells increases resistance to PARPi and other DNA damaging strategies, which could be 
occurring in the human tumors with low 53BP1 (Bouwman et al., 2010; Bunting et al., 2010). 
Thus, doubly deficient cells in BRCA1 and 53BP1 are ‘synthetically viable’ (Aly & Ganesan, 
2011). It is interesting to speculate that upregulating 53BP1 levels would render BRCA1-
deficient cells and tumors ‘synthetically lethal’ to PARPi treatment and other DNA damaging 
strategies. 
 
53BP1 BRCA1
NHEJ HR
53BP153BP1
End joining End resection
RPA coating ssDNA
RAD51
RAD51
RAD51 displaces RPA
Homology search & strand invasion
Figure 1-2. 53BP1 blocks end resection to facilitate NHEJ.
When BRCA1 levels are low, 53BP1 accumulates at double
strand breaks and blocks end resection, a key step for RAD51
coating of ssDNA that drives homology search and strand
invasion during HR. If 53BP1 is lost, end resection is able to
occur and HR is restored.
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1.7 A-Type Lamins 
 A-type lamins are type V intermediate filaments that underlie the inner nuclear 
membrane and form a meshwork throughout the nucleoplasm, providing nuclear shape and 
stability (Figure 1-3) (Stuurman, Heins, & Aebi, 1998). A-type lamins have been implicated in 
many essential nuclear processes, including DNA replication and repair, gene transcription and 
silencing, positioning of nuclear pore complexes, chromatin remodeling, and nuclear envelope 
breakdown and assembly during mitosis (Goldman, Gruenbaum, Moir, Shumaker, & Spann, 
2002; Gruenbaum, Margalit, Goldman, Shumaker, & Wilson, 2005). Four splice variants of A-
type lamins are encoded by the LMNA gene (Lin & Worman, 1993). The major products are 
lamin A and the smaller lamin C, and the minor products are lamin AΔ10 and lamin C2, which is 
germline specific (Furukawa, Inagaki, & Hotta, 1994; Machiels et al., 1996). A-type lamins are 
only expressed in differentiated cells and are absent in mouse embryos until embryonic day 12 
(Constantinescu, Gray, Sammak, Schatten, & Csoka, 2006). Almost all adult somatic cells in 
mice express lamin A/C, however A-type lamins were found to be absent from cells of the 
immune system such as B and T lymphocytes and cells isolated from the spleen, thymus, or bone 
marrow (Röber, Sauter, Weber, & Osborn, 1990). 
 Lamin A is first translated into prelamin A, which undergoes many processing steps to 
produce mature lamin A.  First, the cysteine in the C-terminal CaaX motif of prelamin A is 
farnesylated, which likely targets the lamins to the inner nuclear membrane (Hennekes & Nigg, 
1994). Then, the last three residues of the CaaX motif are cleaved and the cysteine undergoes 
methyl esterification. Finally, the farnesyl group and 15 C-terminal amino acids are cleaved by 
the zinc metalloproteinase Zmpste24 to produce mature lamin A (Mattout, Dechat, Adam, 
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Goldman, & Gruenbaum, 2006). Similarly to other intermediate filaments, lamins have a central 
α-helical coiled coil rod domain which is flanked by a non-helical N-terminal head domain and 
C-terminal tail domain (Stuurman et al., 1998). A-type lamins interact with several nuclear 
proteins that help lamins carry out their function, including lamins-associated proteins (LAP), 
emerin, nesprin, lamin B receptor (LBR), SUN proteins, and RING finger binding protein 
(RFBP) (Goldman et al., 2002).  
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Figure 1-3. Nuclear distribution of A-type lamins. A-type lamins (in red)
directly underly the inner nuclear membrane to give the nucleus structural support
and shape, where they interact with several membrane proteins. They also form a
meshwork throughout the nucleoplasm that associates with chromatin and
nucleoplasmic proteins. We and others have found that A-type lamins interact with
heterochromatic domains such as telomeres and centromeres.
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More than 300 mutations in the human LMNA gene have been associated with a class of diseases 
termed laminopathies which display a wide range of pathologies (Dechat, Gesson, & Foisner, 
2010). Laminopathies can affect adipose tissue, such as in partial lipodystrophy, muscle tissue, 
such as in several types of muscular dystrophy and cardiomyopathy, and axonal neurons, such as 
in Charcot-Marie-Tooth disorder (Mattout et al., 2006). LMNA mutations also lead to several 
early aging syndromes, the most dramatic and severe being Hutchinson-Gilford Progeria 
Syndrome (HGPS). Patients with HGPS appear normal at birth, but develop severe growth 
abnormalities by two years of age. Children with progeria continue to exhibit characteristics 
associated with aging, and generally die due to atherosclerosis at age 12 to 15. Most human 
progeria cases are caused by a splicing defect in exon 11 of the LMNA gene. A substitution of C 
to T at nucleotide -1824 (G608G) introduces a cryptic donor splice site that results in the deletion 
of 50 amino acids in prelamin A (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). This 
altered form of lamin A is known as progerin and is toxic to the cells. Studies have shown that 
fibroblasts from progeria patients and expression of progerin in cells leads to telomere shortening 
(Decker, Chavez, Vulto, & Lansdorp, 2009; Huang, Risques, Martin, Rabinovitch, & Oshima, 
2008), supporting the notion that telomere attrition is involved in the aging process. 
 Several mouse models to study laminopathies, including progeria, have been generated. 
The LMNA knockout mouse is one of the best characterized, providing data regarding the 
cellular and organismal consequences of loss of A-type lamins functions (Sullivan et al., 1999). 
These mice exhibit structural changes to the nuclear envelope and develop abnormalities that 
resemble the human laminopathy Emery-Dreyfuss muscular dystrophy. They die at two months 
of age with severe growth retardation and cardiomyopathy. A mouse model of progeria that 
expresses the mutant form of lamin A that is missing the final 50 amino acids (progerin) leads to 
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slow growth, bone abnormalities, and loss of fat, and ultimately mice die within 6 weeks (S. H. 
Yang et al., 2006). Cells from these mice exhibit misshapen nuclei and nuclear blebbing, and 
interestingly, treatment with fanesyltransferase inhibitors (FTI) to block progerin targeting to the 
inner nuclear membrane improved the nuclear abnormality phenotype (S. H. Yang et al., 2005). 
The first clinical trials testing the efficacy of FTI treatment in HGPS patients are currently 
ongoing (Gonzalez, Pla, Perez-Sala, & Andres, 2011). Early results indicate that FTI treatment 
led to weight gain in some children and all children participating in the clinical trial had at least 
one measureable improvement in cardiovascular stiffness, bone structure, or audiological status 
(Gordon et al., 2012). 
 Another premature aging mouse model is the Zmpste24 knockout. These mice lack the 
metalloproteinase that is required to cleave the farnesylated tail of prelamin A to produce mature 
lamin A. In cells from these mice, mature lamin A is absent and farnesylated prelamin A 
accumulates at the nuclear periphery. These mice die at around five months of age and exhibit 
growth retardation, cardiomyopathy, muscular dystrophy, lypodystrophy, and a progeroid 
phenotype (Pendás et al., 2002; Varela et al., 2005). A mouse model of progeria has also been 
made by introducing a point mutation in exon 9 of the LMNA gene which was intended to 
generate the L530P substitution in amino acid sequence (Mounkes, Kozlov, Hernandez, Sullivan, 
& Stewart, 2003). This mutation caused mRNA splicing defects between exons 9 and 10 and 
deletion of exon 9 (Δexon9Lmna), which is accompanied by very low levels of mutant lamin 
A/C protein. Although the L530P point mutation is associated with muscular dystrophy in 
humans, the Δexon9Lmna mouse has a progeroid phenotype, with severe growth retardation and 
death within 4-5 weeks, but no evidence of muscular dystrophy. Thus, despite lower levels of A-
type lamins, these mice present with a phenotype that is significantly different from that of 
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LMNA knockout mice, indicating distinct functional consequences of complete loss of A-type 
lamins and expression of low levels of mutant lamin A. Investigating the phenotypic difference 
between mouse models of laminopathies should reveal new insights into the pathogenesis of 
these diseases in humans. 
 A-type lamins have also been implicated in tumorigenesis. Differences in A-type lamins 
expression has been observed in several cancer types and has been linked to increased tumor 
aggressiveness (Prokocimer et al., 2009; Prokocimer, Margalit, & Gruenbaum, 2006). 
Methylation-induced silencing of the LMNA gene has been observed in leukemias, lymphomas, 
and small cell lung cancer, while over-expression is associated with colon carcinoma (Agrelo et 
al., 2005; Broers et al., 1993; Willis et al., 2008). Lamins have also been shown to affect 
pathways that regulate cancer. Importantly, loss of A-type lamins leads to increased proteasomal 
degradation and mislocalization of pRB and p107, key tumor suppressors (Johnson et al., 2004). 
Studies in our own laboratory have revealed novel roles for A-type lamins in maintaining 
genomic stability and the DNA repair pathway (Figure 1-4). LMNA null fibroblasts exhibit 
several telomere defects, including altered nuclear distribution of telomeres, telomere attrition, 
and defects in epigenetic heterochromatin status (Gonzalez-Suarez et al., 2009). We also 
observed an increase in genomic instability characterized by increases in signal free ends 
(telomere loss), chromosome and chromatid breaks, basal γH2AX foci formation characteristic 
of unrepaired DNA damage, and aneuploidy. Interestingly, although there was an increase in 
telomere deprotection, we did not observe an increase in chromosome end-to-end fusions, 
indicating a possible deficiency in the processing of dysfunctional telomeres by NHEJ. We found 
that loss of A-type lamins leads to a marked decrease in 53BP1 levels, due to upregulation of the 
cysteine protease cathepsin L (CTSL), and that this loss of 53BP1 is responsible for the lack of 
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chromosome end-to-end fusions that we observed (Redwood et al., 2011). Loss of A-type lamins 
also causes defects in DNA repair kinetics, specifically loss of the fast phase of repair 
corresponding to NHEJ, which are rescued by ectopic introduction of 53BP1. Furthermore, loss 
of A-type lamins impacts HR as well. We found that depletion of lamins leads to degradation of 
the Rb family members pRB and p107, but not p130. The increase in p130/E2F4 repressor 
complex formation was associated with transcriptional downregulation of BRCA1 and RAD51. 
Consistent with the defects in DNA repair mechanisms, lamins deficient cells exhibited 
increased radiosensitivity (Redwood et al., 2011). These studies demonstrated that A-type lamins 
promote genomic stability by maintaining the levels of key proteins involved in DNA repair 
mechanisms-HR and NHEJ-and in cell cycle regulation –Rb family members-.  
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1.8 Cathepsin L 
Given that loss of A-type lamins leads to destabilization of 53BP1, we sought to 
determine how 53BP1 levels were being reduced. The loss of 53BP1 was due to a post-
translational effect on protein stability, as 53BP1 transcripts levels in LMNA null cells remained 
constant. Therefore, we decided to test if the proteasome or a cysteine protease, cathepsin L 
(CTSL), could be responsible for the degradation of 53BP1. We investigated CTSL because a 
previous study had shown that in the Zmpste24 knockout mouse model of progeria, levels of 
CTSL were elevated in liver and heart tissues (Varela et al., 2005). We showed that 53BP1 levels 
were stabilized in LMNA null cells when treated with a proteasome inhibitor and with an 
inhibitor specific for cathepsin L (Gonzalez-Suarez et al., 2011). The stabilization of 53BP1 with 
the CTSL inhibitor was more profound than with the proteasome inhibitor, so we decided to 
investigate the role of CTSL further. Indeed, we found that upon loss of A-type lamins the levels 
of 53BP1 were decreased concomitantly with transcriptional upregulation of CTSL. Depletion of 
CTSL in LMNA null cells rescued 53BP1 levels as well as the defect in DNA repair kinetics 
upon loss of A-type lamins, while overexpression of CTSL in wild type cells led to the 
degradation of 53BP1, unveiling a novel mechanism for regulation of 53BP1 protein levels 
(Figure 1-5) (Gonzalez-Suarez et al., 2011). 
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Cathepsin L is a papain-like lysosomal cysteine protease, of which there are 11 currently 
known (Turk & Guncar, 2003). Cathepsin L is an endopeptidase that is produced as 
preprocathepsin L, transported to the endoplasmic reticulum and through the Golgi apparatus in 
secretory vesicles as procathepsin L and activated by autolysis at acidic pH in lysosomes, where 
it is stored (Lankelma et al., 2010). Cathepsin L knockout mice exhibit hair loss, thickening of 
Figure 1-5. Cathepsin L regulation of 53BP1. (Left) A-type lamins prevent degradation
of 53BP1 by stabilizing CTSL mRNA. Overexpression of CTSL promotes the transport of
53BP1 out of the nucleus and its degradation. (Right) Loss of A-type lamins leads to
upregulation of CTSL and its accumulation in the nucleus, which leads to degradation of
53BP1 and its accumulation in the cytoplasm. Treatment with vitamin D inhibits CTSL
activity, likely through upregulation of cystatins, and stabilizes 53BP1 levels.
Gonzalez-Suarez  et al. 2010
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the skin, and abnormal spermatogenesis (Roth et al., 2000; Wright, Smith, Kerr, & Charron, 
2003), and older mice develop dilated cardiomyopathy (Stypmann et al., 2002). 
 Cathepsin L has been shown to be upregulated in a wide variety of cancers, including 
colon, lung, gastric, breast, head and neck carcinomas, melanomas and gliomas (Jedeszko & 
Sloane, 2004; Kos et al., 1997). CTSL degrades components of the extracellular matrix such as 
fibronectin, laminin, and collagen types I and IV (Skrzydlewska, Sulkowska, Koda, & 
Sulkowski, 2005), which could help promote invasion and metastasis. In most studies, treatment 
with cathepsin inhibitors decreased invasion and metastasis of several types of cancer (Lankelma 
et al., 2010). 
 Cathepsin L has also been identified in the nucleus. A study showed that a truncated 
CTSL isoform is present in the nucleus where it proteolytically processes the CDP/Cux 
transcription factor to accelerate entry into S phase, indicating that CTSL could have a role in the 
cell cycle regulation and cell proliferation (Goulet et al., 2004). CTSL in the nucleus is also 
responsible for cleavage of the histone H3 N-terminal tail during mouse embryonic stem cell 
differentiation (Duncan et al., 2008). Studies in our laboratory have also revealed novel roles of 
CTSL in the nucleus. Loss of A-type lamins leads to upregulation of CTSL and accumulation of 
the active enzyme in the nucleus, which leads to the degradation of 53BP1 and its accumulation 
into the cytoplasm (Gonzalez-Suarez et al., 2011). 
 A study had previously shown that treatment of human colon cancer cells with the active 
metabolite of vitamin D (1α,25-dihydroxyvitamin D3) induced vitamin D receptor (VDR) 
binding to the promoter of cystatin D, an endogenous inhibitor of CTSL, and led to increased 
levels of cystatin D mRNA and protein levels (Alvarez-Díaz et al., 2009). Interestingly, we 
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showed that inhibition of cathepsin L with vitamin D treatment in LMNA null cells stabilizes 
53BP1 levels and rescues the defects in DNA repair kinetics and the processing of dysfunctional 
telomeres by NHEJ (Figure 1-5) (Gonzalez-Suarez et al., 2011). These studies provide an 
unprecedented method for regulating levels of 53BP1: inhibition of CTSL via treatment with 
vitamin D or cathepsin inhibitors. 
1.9 Triple-negative breast cancer 
 Breast cancers have been divided into five main subtypes: two that are estrogen receptor 
positive (luminal A and luminal B) and three that have estrogen receptor negative tumors 
(normal-breast like, basal-like, and HER2 positive) (Constantinidou, Jones, & Reis-Filho, 2010; 
Sorlie et al., 2003; Sørlie et al., 2001). The luminal A and B subgroups have the best prognoses 
while the HER2 positive and basal-like tumors are more aggressive and have worse prognoses. 
The term basal-like refers to gene expression similarities between these types of tumors with 
normal basal epithelial cells of the breast and the increased expression of basal-like cytokeratins 
(Nanda, 2011). The triple-negative breast cancers (TNBC), which account for 15% to 20% of all 
breast cancers, are characterized by the absence of immunohistological staining of estrogen 
receptor, progesterone receptor, and HER2, and most TNBCs exhibit basal-like characteristics 
(Dent et al., 2007; Nanda, 2011). TNBCs are very aggressive and difficult to treat, as they cannot 
be treated with endocrine therapy or HER2 inhibitors due to the lack of hormone receptors and 
HER2 expression (Reis-Filho & Tutt, 2008). Additionally, up to 90% of tumors that have 
germline mutations in BRCA1 are triple-negative (Thompson & Easton, 2002). Triple-negative 
and BRCA1-mutated tumors tend to be more common in younger women and African American 
women, and have a higher risk of metastasis and recurrence than other breast cancers (Dent et 
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al., 2007; Nanda, 2011). 
 Although TNBCs are characterized by the lack of hormone receptors and HER2, and 
their tendency to be basal-like, there is clear histopathological evidence that there are many 
differences between individual TNBCs (Rakha et al., 2007; B Weigelt et al., 2008; Britta 
Weigelt, Baehner, & Reis-Filho, 2010; Britta Weigelt & Reis-Filho, 2009). While chemotherapy 
treatment has shown moderate success in treating TNBCs, the differential response of these 
tumors to chemotherapeutic drugs provides further evidence of the heterogeneity of this class of 
tumors (Constantinidou et al., 2010; Nanda, 2011). It is clear that identification of new 
diagnostic characteristics or markers of TNBCs or BRCA1-mutated cancers could serve to 
predict efficacy of different treatments based on individual tumor statuses. 
 One very promising treatment strategy for TNBCs and BRCA1-mutated cancers is the 
use of PARP inhibitors combined with chemotherapy or radiation to improve outcomes, given 
that these tumors commonly have defects in HR. However, many tumors become resistant to 
PARP inhibitor treatment. Recent evidence suggests that loss of 53BP1 is associated with TNBC 
and contributes to the resistance of these tumors to PARP inhibitors by partially rescuing the 
BRCA1-deficient phenotype (Bouwman et al., 2010; Bunting et al., 2010). Given that studies in 
our laboratory have identified a novel mechanism of regulation of 53BP1, that is, cathepsin L-
mediated degradation, we investigated here whether activation of cathepsin L is one of the 
mechanisms responsible for lowering 53BP1 levels in TNBC and BRCA1-mutated tumor cells. 
Furthermore, we tested if upregulation of 53BP1 using cathepsin L as an effector leads to 
increased sensitivity to DNA damaging strategies, and as a consequence in tumor cell death. 
Lastly, we investigated whether cathepsin L can serve as a novel biomarker for TNBC and 
BRCA1 related tumors with potential predictive value for drug response.  
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CHAPTER TWO 
 
BRCA1-deficient cells activate cathepsin L-mediated degradation of 
53BP1 to overcome genomic instability and growth arrest 
 
 
 
 
  
40 
 
2.1 Abstract 
 BRCA1-mutated breast cancers, which are most often also characterized as being triple-
negative breast cancers (TNBC) are very difficult to treat and have poor prognosis. BRCA1 
deficiency is associated with defects in HR, which leads to genomic instability and cell death. 
Thus, investigators have been trying to determine how BRCA1-deficient tumor cells are able to 
overcome genomic instability and proliferation defects. Several studies published in 2010 
showed that loss of 53BP1 partially rescues the BRCA1-deficient phenotype, including the 
embryonic lethality in mice expressing a loss-of-function mutant form of BRCA1 (deletion of 
BRCA1 exon 11) (Bouwman et al. 2010; Bunting et al. 2010; L. Cao et al. 2009). 53BP1 loss 
also rescued HR and rendered cells resistant to PARP inhibitor treatment, drugs on the forefront 
of cancer treatment that are effective in cells deficient in HR. The model that was proposed is 
that when BRCA1 is absent, the presence of 53BP1 at a DNA double strand break blocks DNA 
end resection and shifts DNA repair to error prone NHEJ while loss of 53BP1 allows end 
resection and HR. Therefore, it is tempting to speculate that raising levels of 53BP1 in the 
context of BRCA1 deficiency could shift DNA repair towards NHEJ and render cells sensitive to 
PARPi and other DNA damaging strategies. However, until studies performed in our laboratory 
identifying the cysteine protease cathepsin L (CTSL) as a regulator of 53BP1 levels, little was 
known about the regulation of this DNA repair factor. Here, we show that upon loss of BRCA1, 
breast cancer cells activate CTSL-mediated degradation of 53BP1 and that CTSL is responsible 
for the decrease in 53BP1 levels. Activation of this pathway allows BRCA1-deficient cells to 
overcome genomic instability and growth arrest. Furthermore, inhibition of CTSL with a 
cathepsin inhibitor or vitamin D rescues levels of 53BP1. Raising 53BP1 levels in BRCA1-
deficient cells rescues NHEJ and inhibits HR, thereby causing an increase in genomic instability 
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following irradiation or PARPi treatment, and compromising proliferation. Thus, inhibiting 
CTSL via specific inhibitors or vitamin D could represent a novel therapeutic strategy for 
treatment of breast cancers with the poorest prognosis. 
2.2 BRCA1-deficient cells activate CTSL mediated degradation of 53BP1 to 
overcome growth arrest 
Previous studies have demonstrated that loss of 53BP1 rescues the BRCA1-deficient 
phenotype (Bouwman et al. 2010; Bunting et al. 2010; L. Cao et al. 2009). Here, we investigated 
whether breast tumor cells are able to downregulate 53BP1 upon loss of BRCA1 in order to 
restore proliferation and if CTSL could be a mechanism responsible for the depletion of 53BP1. 
To recapitulate a BRCA1-deficient phenotype, we knocked down BRCA1 via lentiviral 
transduction using specific short hairpin RNAs (sh RNAs) in MCF7 cells (Figure 2-1). We 
chose MCF7 cells because they are a 
human breast cancer cell line that is 
proficient in BRCA1 and 53BP1 and 
could therefore be used to monitor the 
effects of depletion of either protein. 
MCF7 cells are positive for estrogen 
receptor and progesterone receptor 
(Brooks, Locke, and Soule 
1973)(Levenson and Jordan 1997). 
Consistent with previous findings in 
human fibroblasts (Tu et al. 2011), MCF7 
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Figure 2-1. Depletion of
BRCA1 in MCF7 cells.
MCF7 cells were
lentivirally transuced
with a shRNA for
depletion of BRCA1 (sh
BRCA) or a control
shRNA (sh scr) and the
levels of BRCA1 were
assayed by western blot
immediately after
selection. A full gel is
shown for BRCA1 on the
right.
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cells depleted of BRCA1 entered a growth arrest while control short hairpin cells continued to 
grow exponentially (Figure 2-2A). We monitored levels of 53BP1 and CTSL by western blot 
while the cells were 
growth arrested and found 
no difference in protein 
levels between controls 
and BRCA1-depleted 
cells (Figure 2-2B). 
Interestingly, after 
approximately two weeks 
in culture, the BRCA1-
deficient cells resumed 
proliferation, albeit at a 
slower rate than control 
cells (Figure 2-2C). 
When we measured the 
protein levels of CTSL 
and 53BP1 in these 
BRCA1-deficient cells 
that Overcome Growth 
Arrest (herein referred to 
as BOGA cells, for 
clarity), we found decreased 53BP1 and increased CTSL levels (Figure 2-2D). 
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Figure 2-2. Bypass of growth arrest following BRCA1 loss is
associated with upregulation of CTSL and degradation of 53BP1.
(A) Proliferation rate of MCF7 cells shows that depletion of BRCA1
induces a growth arrest for up to 14 days. (B) Western blots show
53BP1 and CTSL (Pro-CTSL and Active CTSL) levels in growth-
arrested cells. (C) Proliferation rate of BRCA1-deficient cells that
overcome growth arrest (BOGA cells). (D) Western blots show
levels of BRCA1, 53BP1, and CTSL in control and BOGA cells
(representative experiment of 25 biological repeats).
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Figure 2-3. CTSL-mediated degradation of 53BP1
upon depletion of BRCA1 in different breast
cancer cells and using several short hairpin RNAs.
(A) MDA-MB-231 breast cancer cells were
transduced with sh scr and sh BRCA1. Western blots
performed in cells that bypass growth arrest (BOGA)
show upregulation of CTSL and degradation of
53BP1. (B) MCF7 cells were transduced with 5
different sh RNAs specific for BRCA1 or sh scr.
Western blots show a reduction of BRCA1 with all
hairpins, increased CTSL levels with 4 hairpins, and
degradation of 53BP1 with hairpins #3 and #5.
However, the depletion of BRCA1 and the activation
of CTSL-mediated degradation of 53BP1 was
modest. (C) We combined sh RNAs #1 and #2 for
depletion of BRCA1. We achieved a marked
depletion of BRCA1 and a clear growth arrest.
Importantly, BOGA cells generated with these
hairpins activated CTSL-mediated degradation of
53BP1. Overall, loss of BRCA1 with different sh
RNAs activates CTSL-mediated degradation of
53BP1 in different types of breast cancer cells.
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We also observed this signature of low 53BP1 and high CTSL in another breast tumor cell line, 
MDA-MB-231 (Figure 2-3A), as well as with several other sh RNAs for depletion of BRCA1 
(Figure 2-3B). We next monitored levels of BRCA1, CTSL, and 53BP1 transcripts by qRT-PCR 
(Figure 2-4A). BRCA1 depleted cells exhibited a significant decrease in BRCA1 while CTSL 
transcripts levels were significantly increased. Interestingly, there was no significant change in 
53BP1 transcripts levels, indicating a posttranslational effect on 53BP1 protein stability. To 
confirm that BRCA1 loss leads to the decrease in 53BP1 levels, we overexpressed BRCA1 via 
transient transfection in BOGA cells and in the human BRCA1-deficient breast tumor line 
HCC1937. We monitored levels of 53BP1 and found that BRCA1 reconstitution stabilizes 
53BP1 levels in both cell lines (Figure 2-4B), indicating a novel function for BRCA1 in 
regulating 53BP1 levels. 
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Figure 2-4. Transcripts levels upon BRCA1 depletion and western blot after BRCA1
reconstitution in BRCA1-deficient cells (A) Relative expression of BRCA1, CTSL, and 53BP1 in
control and BOGA cells as determined by qRT-PCR. The average  standard deviation of 3
independent experiments is shown. * p-value of statistical significance (p≤0.05). NS, no statistically
significant differences. (B) Western blots show BRCA1 and 53BP1 levels upon reconstitution of
BRCA1 by transient transfection into BRCA1-deficient cells lines – BOGA cells (left panel) and
HCC1937 cells (right panel). Transfection of an empty vector (EV) was used as control. Β-tubulin
was used as loading control.
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 Given that loss of 53BP1 in a BRCA1-deficient context allows cells to proliferate, we 
wanted to determine if depletion of 53BP1 prior to BRCA1 depletion leads to a bypass of the 
growth arrest. We were able to obtain a marked decrease in both 53BP1 and BRCA1 using 
specific sh RNAs (Figure 2-5A). Importantly, cells depleted of 53BP1 prior to BRCA1 
continued to proliferate and did not exhibit the characteristic growth arrest upon BRCA1 
depletion, although these cells proliferated slower than controls (Figure 2-5B). Interestingly, 
cells that were depleted of 53BP1 prior to depletion of BRCA1 still upregulated CTSL (Figure 
2-5C), indicating the upregulation of CTSL is independent of 53BP1 levels. 
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We next tested if CTSL is responsible for the decrease in 53BP1 protein levels in 
BRCA1-deficient cells by depleting CTSL in control and BOGA cells. Importantly, depletion of 
CTSL in BOGA cells rescued levels of 53BP1 protein to the same level as control cells (Figure 
2-6A) without having an effect on BRCA1 transcripts levels (Figure 2-6B). We also observed a 
slight increase in BRCA1 protein levels in BOGA cells depleted of CTSL, suggesting a possible 
feedback mechanism of CTSL on BRCA1 protein levels.  
 To confirm that CTSL is responsible for the decrease in 53BP1 in BRCA1-deficient cells, 
we treated BOGA cells with CTSL inhibitors. Previous studies in colon cancer cells had shown 
that vitamin D inhibits the activity of cathepsins (Alvarez-Díaz et al. 2009). The mechanism 
involves the upregulation by vitamin D receptor (VDR) of cystatin D, an endogenous inhibitor of 
cathepsins, including CTSL. We also previously showed that vitamin D inhibits CTSL activity 
and stabilizes 53BP1 protein levels in MEFs (Gonzalez-Suarez et al. 2011). Thus, we determined 
whether vitamin D treatment could stabilize 53BP1 protein levels in BRCA1-deficient cells. We 
show that treatment of BOGA cells with vitamin D (1α,25-dihydroxyvitamin D3) for 24 hours 
stabilizes the levels of 53BP1 (Figure 2-6C). In addition, vitamin D stabilizes levels of p107, an 
Rb family member that is a known target of CTSL-mediated degradation (Redwood, Gonzalez-
suarez, and Gonzalo 2011). Similarly, treatment of BOGA cells with the cathepsin inhibitor E-64 
increased 53BP1 protein levels (Figure 2-6D). Overall, these data demonstrate that growth 
arrested BRCA1-deficient cells activate CTSL mediated degradation of 53BP1 to bypass the 
growth arrest. Furthermore, depletion or inhibition of CTSL increases 53BP1 levels in BRCA1-
deficient cells with potential therapeutic effects. 
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Figure 2-6. CTSL is responsible for the degradation of 53BP1 in
BOGA cells. (A) Control and BOGA cells were transduced with sh
CTSL or sh luciferase and the levels of CTSL, BRCA1, and 53BP1
monitored by western. Note how depletion of CTSL rescues the
levels of 53BP1 in BRCA1-deficient cells. (B) Graphs show relative
expression of CTSL (left graph) and BRCA1 (right graph) in the
different cell lines as determined by qRT-PCR. Note the marked
downregulation of CTSL transcripts in control and BOGA cells
transduced with sh CTSL. The average of 3 independent experiments
is shown. * p-value of statistical significance (p≤0.05). (C) Control
or BOGA cells were treated with vitamin D (10-7M) or vehicle
(BGS) for 24 hr. and the levels of 53BP1 and p107, a known target
of CTSL degradation, were monitored by western. (D) Control or
BOGA cells were incubated with the broad cathepsin inhibitor E-64
(10 µM) or with vehicle (H2O) for 24 hr., and the levels of 53BP1
and CTSL monitored by western. Note how inhibition of cathepsin
activity stabilizes 53BP1 protein (representative experiment of 2
biological repeats).
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2.3 CTSL-mediated degradation of 53BP1 rescues HR defects in BRCA1-
deficient cells 
BRCA1 plays a key role in DNA double strand break repair by HR and is involved in 
facilitating end resection at breaks and formation of RAD51 coated filaments that are necessary 
for HR to occur (Bhattacharyya et al. 2000; Moynahan et al. 1999; Brian P Schlegel, Jodelka, 
and Nunez 2006; Scully, J Chen, Plug, et al. 1997; Scully, J Chen, Ochs, et al. 1997; Snouwaert 
et al. 1999; Sung et al. 2003). Interestingly, a previous study had demonstrated that loss of 
53BP1 in BRCA1-deficient cells partially rescues HR and recruitment of RAD51 at ionizing 
radiation-induced foci (IRIF) (Bunting et al. 2010). Here, we determined how CTSL mediated 
degradation of 53BP1 impacts on 53BP1 and RAD51 foci formation in BRCA1-deficient cells. 
We used the presence or absence of 53BP1 or RAD51 IRIF as readout of NHEJ or HR 
proficiency, respectively. Growth arrested MCF7 cells following BRCA1 depletion are able to 
form 53BP1 IRIF (Figure 2-7A), consistent with normal protein levels of 53BP1 in growth 
arrested cells (Figure 2-2B). As we expected, BOGA cells were unable to form 53BP1 IRIF 
(Figure 2-7B), consistent with the decrease in 53BP1 protein levels (Figure 2-2D). Given that 
CTSL inhibition rescues 53BP1 protein levels, we sought to determine if treatment of BOGA 
cells would rescue 53BP1 IRIF formation. Indeed, BOGA cells treated with vehicle were unable 
to form 53BP1 foci formation while treatment with vitamin D for 24 hours rescued the formation 
of 53BP1 foci (Figure 2-7C), which is quantitated in Figure 2-7D, indicating a possible shift 
towards NHEJ upon CTSL inhibition. 
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Figure 2-7. Regulation of 53BP1 IRIF in BOGA cells by vitamin D treatment. (A)
Immunofluorescence to detect 53BP1 IRIF in control (sh scr) and growth-arrested
BRCA1-depleted cells (sh BRCA1) 1 hr. after 8 Gy of IR. (B) The same assay was
performed as in (A), but after bypass of growth arrest (BOGA cells). (C)
Immunofluorescence performed in control and BOGA cells treated with vitamin D or
vehicle 24 hr. prior to IR. Note how treatment with vitamin D restores 53BP1 IRIF in
BOGA cells. (D) Graph shows the percentage of cells that form 53BP1 IRIF in the
presence of vitamin D or vehicle. Cells with >10 53BP1 IRIF were considered positive. At
least 1000 cells were analyzed per condition.
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In contrast to 53BP1, RAD51 recruitment to IRIF was inhibited in growth arrested cells 
shortly after BRCA1 depletion (Figure 2-8). However, once the BRCA1-deficient cells resumed 
proliferation, RAD51 IRIF formation 
was rescued at 1 hour post irradiation 
(Figure 2-9A). This rescue was not due 
to an increase in BRCA1 levels, as 
BOGA cells were unable to form 
BRCA1 labeled IRIF (Figure 2-10). 
We next tested whether CTSL 
mediated degradation of 53BP1 was 
responsible for rescuing RAD51 IRIF 
formation in BOGA cells. First, we 
showed that stabilization of 53BP1 in 
BOGA cells by treatment with vitamin 
D inhibited RAD51 IRIF formation (Figure 2-9B), revealing an unprecedented role for vitamin 
D in modulating HR. Similarly, depletion of CTSL reduces the ability of BOGA cells to recruit 
RAD51 to double-strand breaks (Figure 2-9C). Intriguingly, while control cells formed RAD51 
foci for up to 6 hours post irradiation, the percentage of BOGA cells positive for RAD51 IRIF 
decreased significantly over time (Figure 2-11), indicating that 53BP1 loss in BOGA cells does 
not completely compensate for the depletion of BRCA1. It is unclear what the cause of this 
gradual decrease in RAD51 foci over time is, but we speculate that it could be due to an inability 
to recruit RAD51 to foci or an inability to retain RAD51 at the double-strand break in the 
absence of BRCA1.  
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These studies demonstrate that CTSL mediated degradation of 53BP1 in BOGA cells rescues HR 
defects exhibited by BRCA1-deficient cells, promoting survival. Furthermore, CTSL inhibition 
and the stabilization of 53BP1 in BRCA1-deficient cells could be utilized as a novel strategy to 
inhibit HR and cause genomic instability. 
2.4 Consequences of CTSL mediated degradation of 53BP1 for DNA repair 
and genomic stability 
To determine the functional consequences of CTSL mediated degradation of 53BP1, we 
evaluated the kinetics of DNA double strand break repair by performing comet assays under 
neutral, non denaturing conditions (Olive, Banáth, and Durand 2012). In the comet assay, cells 
irradiated with 8Gy are collected at 30 minutes intervals post IR and fixed in agarose. Single cell 
gel electrophoresis is performed, DNA is stained with ethidium bromide, and pictures are taken 
on a microscope. Fragmented DNA migrates in the agarose and appears as a comet, and a 
quantitative score known as olive moment is calculated based on the intensity and lengths of 
comet tails. When olive moments are graphed, a characteristic biphasic curve emerges where a 
fast phase of DNA repair occurs in the first 30 minutes post irradiation, followed by a slow phase 
of repair. The fast phase of DNA double strand break repair has been attributed to classical or 
DNA-PK dependent NHEJ, as depletion of factors required for this pathway significantly slows 
the fast kinetics of repair (Iliakis et al. 2004). In contrast, the slow phase of repair has been 
attributed to alternative or backup NHEJ or HR. Figure 2-12 shows that BOGA cells exhibit 
defects in the fast phase of repair, indicating a defect in classical NHEJ. This result is consistent 
with our previous finding that upregulation of CTSL in MEFs leads to defects in the fast phase of 
repair due to degradation of 53BP1 (Gonzalez-Suarez et al. 2011). Furthermore, by inhibiting 
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Figure 2-12. Effect of CTSL inhibition on DNA repair
kinetics. Neutral comet assays after 8 Gy of IR show higher
olive moments, and thus defects in the fast-phase of DNA
repair in BOGA cells. Inhibition of CTSL activity by
treatment with vitamin D (10-7 M) 24 hr. pre-IR rescues
defects in DNA DSBs repair.
CTSL via vitamin D treatment and stabilizing 53BP1 levels (Figure 2-6C), DNA double-strand 
break repair kinetics are rescued and mirror those of control cells (Figure 2-12). These results 
suggest that CTSL mediated 
degradation of 53BP1 hinders 
NHEJ in BRCA1-deficient 
cells. However, these cells are 
still able to repair DNA double-
strand breaks, albeit at a lower 
rate, suggesting that repair by 
HR or alternative NHEJ might 
remain relatively intact. This is 
consistent with the ability for 
RAD51 foci to form at early 
times post irradiation. 
Cells deficient in HR become dependent on alternative pathways of DNA double strand 
break repair, which often leads to complex chromosomal aberrations that trigger cell cycle arrest 
or death. It has been shown that loss of 53BP1 is sufficient to reduce the extent of aberrant 
chromosomal structures in BRCA1-deficient cells (Bunting et al. 2010). Given that BOGA cells 
are defective in NHEJ and stabilization of 53BP1 levels rescues this error-prone DNA double-
strand break repair pathway, we determined if CTSL inhibition increases genomic instability 
after irradiation by analyzing metaphase spreads. We did not find a profound increase in 
chromosome aberrations after irradiation in BOGA cells (Figure 2-13A), consistent with the 
deficiency in BRCA1 and 53BP1.  
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Figure 2-13. Effect of CTSL inhibition on genomic stability in BOGA cells. (A) Control and
BOGA cells were incubated with vehicle control (C) or vitamin D (VD) for 24 hr. prior to irradiation
with 2 Gy (IR). Cells collected 24 hr. post-IR were analyzed for genomic instability by quantitating
the percentage of metaphases presenting with chromosomal aberrations, as shown in the images.
N, number of independent experiments (50 metaphases analyzed per condition in each
experiment). (B) Control and BOGA cells were incubated with the cathepsin inhibitor (E-64) or
vehicle control (C) for 24 hr. prior to IR, and the extent of genomic instability assessed as in (A). (C)
Graph shows relative numbers of BOGA cells 4 days after treatment with IR, vitamin D, or the
combination of both. Treatment protocol as in (A). (D) Graph shows relative numbers of BOGA cells
4 days after treatment with IR, E-64, or the combination of both. Treatment performed as in (B). All
values expressed as mean ± SEM. N, number of independent experiments; *p value of statistical
significance (*p≤0.05).
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However, stabilization of 53BP1 by vitamin D treatment significantly increased the percentage 
of metaphases exhibiting aberrant chromosomes after irradiation (Figure 2-13A). Similarly, 
stabilization of 53BP1 in BOGA cells by treatment with the cathepsin inhibitor E-64 markedly 
increased genomic instability after irradiation (Figure 2-13B). To determine if the increase in 
genomic instability caused by 53BP1 stabilization in BOGA cells has a negative effect on 
proliferation, we monitored the cells’ ability to recover from irradiation after treatment with 
vitamin D or E-64. Indeed, irradiated cells treated with vitamin D (Figure 2-13C) or E-64 
(Figure 2-13D) exhibited decreased proliferation compared to controls. Thus, CTSL inhibition 
could represent a novel strategy to induce radiosensitivity in specific types of breast tumors. 
To confirm that inhibition of CTSL mediated degradation of 53BP1 is responsible for the 
increase in chromosomal aberrations after irradiation, we analyzed metaphase spreads for 
genomic instability in BOGA cells depleted of CTSL. Similarly to cells in which CTSL is 
inhibited, CTSL depleted BOGA cells showed a marked increase in chromosomal aberrations 
after irradiation when compared to cells depleted of either BRCA1 or CTSL alone (Figure 2-
14A). Furthermore, we determined if the effect of vitamin D increasing genomic instability after 
irradiation in BOGA cells is mediated by 53BP1 by monitoring chromosomal aberrations in cells 
doubly depleted of BRCA1 and 53BP1. If stabilization of 53BP1 is responsible for the increase 
in genomic instability after vitamin D treatment, we would expect that loss of 53BP1 blocks 
vitamin D’s effect on inducing genomic instability. In 53BP1/BRCA1 doubly depleted cells the 
combination of vitamin D and ionizing radiation does not result in such profound genomic 
instability (Figure 2-14B) as that observed when BOGA cells are treated with vitamin D (Figure 
2-13A).  
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Figure 2-14. Chromosomal aberrations in response to IR.
(A) BOGA cells transduced with a shRNA control (sh scr) or
a sh RNA for CTSL were irradiated with 2 Gy and the
percentage of cells with aberrant metaphases was quantified
24 hr. post-IR. A total of 400 metaphases were analyzed (50
per condition). (B) MCF7 cells depleted of 53BP1 and
BRCA1 (sh 53BP1 + sh BRCA1) were treated with vitamin
D or vehicle 24 hr. prior to IR, and the percentage of
metaphases with aberrant chromosomes were quantitated. A
total of 400 metaphases were analyzed (50 per condition).
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These results demonstrate that vitamin D exerts its effect in part by stabilizing 53BP1levels and 
that the extent of CTSL mediated degradation of 53BP1 is a key determinant of the ability of 
BRCA1-deficient cells to deal with the DNA damage generated by irradiation and putatively 
other genotoxic agents. 
Cells deficient in HR, such as BRCA1-deficient or mutated cells, are exquisitely sensitive 
to PARP inhibitors (Bryant et al. 2005; Drew et al. 2011; Farmer et al. 2005). PARP inhibitors 
block a key step in repair of single stranded DNA breaks. When single strand breaks are 
unrepaired they become double strand breaks, which are repaired by HR. Importantly, previous 
studies demonstrated that loss of 53BP1 
allows cells to overcome the BRCA1-
deficient phenotype and that these cells are 
resistant to PARP inhibitor treatment (Aly 
and Ganesan 2011; Bunting et al. 2010). 
We assessed whether stabilization of 53BP1 
in BOGA cells would increase the extent of 
genomic instability induced by the PARP 
inhibitor EB-47. Figure 2-15 shows that 
treatment of BOGA cells with the PARP 
inhibitor does not result in genomic 
instability, in agreement with the resistance 
of cells double deficient in 53BP1 and BRCA1 to this treatment. Interestingly, stabilization of 
53BP1 via CTSL inhibition by vitamin D increases the extent of chromosomal aberrations in 
response to the PARP inhibitor. These data suggest that inhibition of CTSL mediated 
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Figure 2-15. Chromosomal aberrations in
response to PARP inhibitors. BOGA cells were
treated with vitamin D (10-7 M) 24 hr. prior to
treatment with the PARPi EB-47 (Pi, 1.2 µg/mL)
for an additional 48 hr. Graph shows the
percentage of metaphases with chromosomal
aberrations. Images show the types of
chromosomal aberrations observed. A total of
400 metaphases were analyzed (100 per
condition).
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degradation of 53BP1 could induce PARP inhibitor sensitivity.  
2.5 Discussion and future experiments 
Triple-negative and BRCA1-mutated cancers are among the most aggressive and difficult 
to treat. Given that these tumors often exhibit defects in HR, exploiting the lack of HR 
capabilities through treatment with DNA damaging agents such as PARP inhibitors, has emerged 
as a promising treatment strategy for these cancers (Foulkes, I. E. Smith, and Reis-Filho 2010). 
However, many of these tumors become mutated to gain HR functionality or acquire it through 
other means (Ashworth 2008; Swisher et al. 2008). Recent studies have shown that 53BP1 loss 
allows BRCA1-deficient cells to re-gain HR functionality and render the cells resistant to PARPi 
and other DNA damaging strategies (Bouwman et al. 2010; Bunting et al. 2010; L. Cao et al. 
2009). Thus, stabilizing 53BP1 levels represents a promising new strategy for treatment of these 
cancers. However, prior to this study, no information was available about how 53BP1 levels are 
downregulated in breast cancer cells. 
Here, we show that CTSL is upregulated following BRCA1 loss in human breast cancer 
cells, and that CTSL is responsible for lowering 53BP1 protein levels, which in turn allows the 
bypass of the characteristic growth arrest upon loss of BRCA1 function. Since previous studies 
in our laboratory have implicated the proteasome in degradation of 53BP1 (Gonzalez-Suarez et 
al. 2011), it is possible that other mechanisms contribute to the loss of 53BP1 in BRCA1-
deficient cells. In addition, a previous study had shown that 53BP1 mRNA levels are 
downregulated in BRCA1-associated tumors and TNBC, which could represent another 
mechanism for 53BP1 regulation (Bouwman et al. 2010). Here, we provide clear evidence that 
depletion or inhibition of CTSL activity stabilizes 53BP1 protein levels and induces genomic 
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instability in BRCA1-deficient cancer cells after treatment with IR or PARPi. Thus, inhibition of 
this pathway via treatment with vitamin D or cathepsin inhibitors could provide a new 
therapeutic strategy for breast cancer. 
CTSL upregulation upon loss of BRCA1 
 In this study, we show that CTSL is transcriptionally upregulated upon loss of BRCA1 to 
raise 53BP1 levels and overcome the growth arrest. Given that BRCA1 has been implicated in a 
whole host of cellular processes including transcriptional regulation, maintenance of 
heterochromatin, regulation of DNA methylation, and miRNA biogenesis, and that little is 
known about how CTSL is regulated in the cell, many questions remain to be answered about 
how BRCA1 loss leads to CTSL upregulation. BRCA1 has been copurified with the RNA 
polymerase II holoenzyme complex (Anderson et al. 1998), indicating that BRCA1 is a 
component of the core transcriptional machinery. BRCA1 has also been shown to associate with 
and stimulate p53 transcription (H. Zhang et al. 1998) which has implications for regulating the 
cell cycle and DNA repair.  
However, in our study the activation of CTSL upon loss of BRCA1 can take upwards of 
two weeks to occur, indicating that CTSL is not likely to be a direct transcriptional target of 
BRCA1. Rather, we speculate that loss of BRCA1 might result in alterations in chromatin 
structure that make the CTSL gene more permissive to transcriptional activation over time. 
BRCA1 has been shown to interact with the histone deacetylases HDAC1 and HDAC2 (Yarden 
and Brody 1999) and with the BRG1 subunit of the chromatin remodeling SWI/SNF complex 
(Bochar et al. 2000). Other studies have shown that BRCA1 maintains heterochromatin structure 
through ubiquitylation of histone H2A (Zhu et al. 2011) and that loss of BRCA1 function leads 
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to global DNA hypomethylation and an open chromatin configuration through its regulation of 
DNMT1 (Shukla et al. 2010). All of these studies suggest that alterations of BRCA1 levels could 
have an effect on the chromatin structure of the CTSL gene promoter. Chromatin 
immunoprecipitation (ChIP) analyses need to be performed on the CTSL promoter to identify 
changes in chromatin marks or to detect binding of chromatin-modifying factors that could 
explain the transcriptional upregulation of the gene. The effect that loss of BRCA1 has on CTSL 
promoter activity can also be measured using a luciferase reporter construct (Bakhshi et al. 2001) 
and promoter mutants can be made to determine which domains of the CTSL promoter are 
important for its upregulation. 
Currently, there is very little information about how the levels of CTSL are regulated in 
the cell. There is ample evidence, however, that activation of Ras leads to increased expression 
of cysteine proteases of the cathepsin family, including CTSL. This has been shown in vitro in 
mouse fibroblasts (Chambers et al. 1992; Denhardt et al. 1987), mouse melanocytes (Donatien et 
al. 1996), and human breast epithelial cells (Lah et al. 1995). As Ras is frequently mutated in 
human cancers, it is no surprise that increased cathepsin L levels are often observed in cancer 
(Chauhan, Goldstein, and Gottesman 1991; Collette et al. 2004). Experiments can be performed 
to determine if Ras or any of its downstream effectors are activated upon loss of BRCA1 in 
breast tumor cells and if overexpression of Ras activates CTSL mediated degradation of 53BP1, 
which would reveal a novel role for Ras in the regulation of a key DNA repair factor. 
Experiments can also be performed to determine if inhibition of Ras using farnesyltransferase 
inhibitors can block CTSL mediated degradation of 53BP1. There is also evidence that the 
transcription factor STAT3 regulates CTSL mRNA and protein levels (Kreuzaler et al. 2011), an 
avenue that can also be studied. Lastly, it remains to be determined whether CTSL-mediated 
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degradation of 53BP1 is activated in different subtypes of breast cancer. 
Another interesting question that arises from this study relates to the similar phenotypes 
observed upon loss of BRCA1 as with loss of A-type lamins. When BRCA1 or A-type lamins 
are depleted, CTSL is transcriptionally upregulated, leading to degradation of 53BP1. 
Interestingly, our previous studies demonstrated that loss of A-type lamins results in 
downregulation of BRCA1 at the transcriptional level. Thus, it is possible that downregulation of 
BRCA1 is behind the activation of CTSL-mediated degradation of 53BP1 in lamins-deficient 
cells, a hypothesis that remains to be tested. If this were the case, we would expect that 
downregulation of 53BP1 and BRCA1 via depletion of A-type lamins would contribute to 
bypass the growth arrest that accompanies the loss of BRCA1. In addition, reconstitution of 
BRCA1 into lamins-deficient cells could restore the levels of 53BP1, demonstrating a novel 
functional interplay between DNA repair factors and lamins. Characterizing the relationship 
between these proteins could have a great impact on our understanding of molecular mechanisms 
of cancer and laminopathies.  
Vitamin D and cathepsin inhibitors can modulate DNA repair pathway choice 
 In this study, we uncover an unprecedented role for vitamin D and cathepsin inhibitors in 
the regulation of DNA double strand break repair pathway choice. By stabilizing 53BP1 levels in 
BRCA1-deficient cells, we show that DNA repair is shifted towards NHEJ and HR is inhibited, 
leading to genomic instability and reduced proliferation when cells are challenged with DNA 
damaging agents such as irradiation or PARP inhibitors. We believe that the upregulation of 
CTSL upon loss of BRCA1 leads to an increase in nuclear CTSL similar to the increase in 
nuclear CTSL observed upon loss of A-type lamins (Gonzalez-Suarez et al. 2011). However, it is 
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unclear whether this nuclear CTSL is degrading 53BP1 in the nucleus or is somehow targeting 
the protein for nuclear export to be degraded in the cytoplasm.  
 Detecting an increase in nuclear CTSL levels in BOGA cells has been an active area of 
research in the laboratory. We have recently had success in detecting nuclear cathepsin L by 
performing immunohistochemistry in MCF7 cells embedded in paraffin blocks. Figure 2-16 
shows that BOGA cells have more nuclei stained with cathepsin L and that the staining is more 
intense compared to control cells. As expected, 53BP1 levels are clearly reduced in BOGA cells.  
sh scr
sh BRCA1
(BOGA Cells)
53BP1
Nuclear
Cathepsin L
Hscore = 60
Hscore = 30Hscore = 120
Hscore = 30
Figure 2-16. High nuclear CTSL and low 53BP1 in BOGA cells. Immunohistochemistry
of control (sh scr) and BRCA1 depleted (sh BRCA1) MCF7 cells embedded in paraffin
blocks was performed using antibodies recognizing CTSL and 53BP1. Note that BOGA cells
have increased nuclear CTSL staining and lower 53BP1. Histochemical scores (Hscore) are
indicated below each micrograph.
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The histochemical scores (Hscore), which are a semi-quantitative measurement of 
immunohistochemical staining that takes into account the percentage of positive cells and 
intensity of the stain, are indicated below each micrograph. We have also shown that nuclear 
CTSL is upregulated in triple-negative and BRCA1-mutated tumors by immunohistochemistry 
(see Chapter 3). We have also attempted subcellular fractionation experiments to measure CTSL 
in the nucleus by western blot, but these experiments have been unsuccessful, possibly due to the 
levels being too low to be detected in these cells. We have also attempted to construct a 
cathepsin L species lacking the signal peptide which excludes it from the endoplasmic reticulum 
and that has been previously shown to be targeted to the nucleus (Goulet et al. 2004), but 
following transduction of the plasmid the cells died, possibly due to toxicity from too much 
CTSL in the nucleus. 
 Altogether, the ability to impact on the choice of DNA repair pathway could have 
profound consequences for cancer therapy. In tumor cells that activate CTSL-mediated 
degradation of 53BP1 as a means to ensure survival, cathepsin inhibition could stabilize 53BP1, 
increase genomic instability, and induce growth arrest and/or cell death, especially in 
combination with irradiation or PARPi. Thus, treatment with vitamin D or CTSL inhibitors could 
represent a new therapeutic strategy for specific types of breast cancer. 
CTSL regulation of BRCA1 and 53BP1 levels during the cell cycle 
This study shows that in cells that are growth arrested by depletion of BRCA1, CTSL 
levels are upregulated to degrade 53BP1. We were interested in determining if cells that are 
growth arrested by other means also activate cathepsin L-mediated degradation of 53BP1. We 
found that growth arresting MCF7 cells in G0/G1 by serum deprivation leads to decreased levels 
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of BRCA1, upregulation of CTSL, and downregulation of 53BP1 (Figure 2-17). 
 
While it is known that BRCA1 levels are low during the G0/G1 phases of the cell cycle (W. Liu 
et al. 2010), we show here that levels of 53BP1 are also low in growth arrested cells. These data 
suggest a functional relationship during the cell cycle where BRCA1 might regulate CTSL 
mediated degradation of 53BP1, and that the growth arrest induced by BRCA1 depletion itself 
could contribute to the activation of CTSL-mediated degradation of 53BP1. Future experiments 
involving growth arrest by different means and depletion or inhibition of cathepsin L during 
growth arrest will be necessary to determine if CTSL regulates 53BP1 and BRCA1 during the 
cell cycle. Intriguingly, we also have preliminary evidence that upregulation of cathepsin L could 
trigger a feedback mechanism that lowers BRCA1 protein levels (experiments are ongoing). This 
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Figure 2-17. Growth arrest by serum starvation leads to increased CTSL
and decreased 53BP1 and BRCA1 levels. The cell cycle profiles of MCF7
cells growing asynchronously or growth arrested for 48 hours by serum
deprivation were analyzed by propidium iodide staining (left panels). Western
blots show increased CTSL levels and decreased 53BP1 and BRCA1 levels
(right panel). (Representative experiment of three biological repeats).
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is supported by studies showing that BRCA1 is a target for degradation by cathepsins, though the 
specific cathepsin was not identified (Blagosklonny et al. 1999).   
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CHAPTER THREE 
 
Discovery of nuclear CTSL, vitamin D receptor, and 53BP1 as a novel triple 
biomarker for triple-negative breast cancer and BRCA1-mutated tumors  
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3.1 Abstract 
 Triple-negative breast cancers (TNBC) are classified immunohistochemically by the 
absence of estrogen receptor, progesterone receptor, and HER2. This classification alone is not 
sufficient to determine the proper treatment course for women with this type of breast cancer, as 
there is evidence of great heterogeneity between triple-negative tumors and the efficacy of 
chemotherapy treatment varies widely between women with these kinds of tumors. Therefore, it 
is important to identify new markers for TNBC to stratify women into groups to determine a 
course of treatment that would be most beneficial. A previous study identified low levels of 
53BP1 in TNBC (Bouwman et al., 2010). Loss of 53BP1 also renders BRCA1-deficient cells 
synthetically viable, and most BRCA1-mutated tumors are triple-negative. Given that we found 
that cathepsin L-mediated degradation of 53BP1 rescues genomic instability and growth arrest in 
BRCA1-deficient cells, we determined whether high CTSL could be a biomarker for sporadic 
TNBC and for breast tumors from patients carrying germline mutations in BRCA1, along with 
low levels of 53BP1. Indeed, we identify nuclear CTSL as a novel biomarker for TNBC and 
BRCA1-related tumors, which correlates inversely with 53BP1. Furthermore, since vitamin D 
inhibits CTSL and stabilizes 53BP1 in vitro, we determined the status of vitamin D receptor 
(VDR), which mediates most of vitamin D’s functions in the cell. We found low nuclear levels 
of vitamin D receptor with low 53BP1 and high nuclear CTSL to be the most common signature 
in TNBC and BRCA1-mutated tumors, thus revealing a novel triple biomarker. Based on our in 
vitro data, we hypothesize that these patients could be treated with vitamin D or cathepsin 
inhibitors to raise 53BP1 levels and render tumors susceptible to PARPi treatment or other DNA 
damaging strategies. We also show that vitamin D treatment has an anti-proliferative effect on 
triple-negative breast tumor cells implanted in mice. 
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 To note, the immunohistochemistry was carried out by Anna Novell and the statistical 
analysis was performed by Montserrat Martinez-Alonso in the laboratory of Xavier Matias-Guiu 
at the University of Lleida in Spain under the guidance of me, Adriana Dusso, and Susana 
Gonzalo. They did wonderful work and I am greatly thankful for their contributions to my thesis. 
3.2 Increased levels of nuclear CTSL in TNBC and tumors from patients with 
BRCA1-germline mutations 
 We have uncovered that BRCA1-deficient cells upregulate CTSL to degrade 53BP1 and 
overcome genomic instability and growth arrest in human breast cancer cells in culture. Similarly 
to the BOGA cells, BRCA1-mutated and triple-negative tumors are able to proliferate and 
overcome genomic instability. Recent studies have demonstrated that loss of 53BP1 is more 
frequent in BRCA1-mutated and triple-negative tumors (Bouwman et al., 2010). Given our 
findings in vitro, we determined whether CTSL-mediated degradation of 53BP1 is activated in 
BRCA1-mutated and triple-negative tumors from human patients. Specifically, given that others 
have found CTSL to be present in the nucleus (Duncan et al., 2008; Goulet et al., 2004) and 
studies in our laboratory shown that upregulation of nuclear CTSL leads to the degradation of 
53BP1 (Gonzalez-Suarez et al., 2011), we investigated whether high nuclear CTSL would 
correlate with low 53BP1 in triple-negative and BRCA-mutated tumors. In addition, given the 
inhibitory effect of vitamin D on this pathway, we monitored levels of nuclear VDR in these 
types of tumors. 
 We performed immunohistochemical (IHC) analyses of multitumor tissue microarrays 
(TMA) constructed with tissue from 249 patients with sporadic breast cancer (Figure 3-1) 
classified into four molecular subtypes: Luminal A, Luminal B, HER2, and triple-negative.  
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Figure 3-1. A new signature for subsets of TNBC patients.
Immunohistochemical analysis was performed in breast tumor tissue
microarrays from 249 patients which included four molecular subtypes:
Luminal A, luminal B, HER2, and triple-negative. Representative images of
IHC labeling with Ki67, ERα, HER2, CTSL, and 53BP1 are shown. Note that
while cytoplasmic CTSL is observed in all tumor subtypes, nuclear CTSL is
markedly upregulated in a subset of TNBC. In addition, TNBC tumors exhibit
a marked decrease in 53BP1.
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Luminal A tumors tend to be estrogen receptor positive and progesterone receptor positive, 
HER2/neu negative, and have the best prognosis out of the four molecular subtypes (Carey et al., 
2006). Luminal B tumors tend to be positive for estrogen receptor, progesterone receptor, and 
Ki67. Luminal B tumors are usually diagnosed at a younger age than luminal A tumors, and have 
a slightly poorer prognosis than luminal A (Arvold et al., 2011; Voduc et al., 2010). HER2 
tumors are positive for HER2/neu and negative for estrogen receptor and progesterone receptor. 
HER2 tumors have a poor prognosis and are prone to recurrence and metastasis (Arvold et al., 
2011; Carey et al., 2006; Voduc et al., 2010). Triple-negative tumors have very poor prognosis 
and are characterized by the lack of estrogen receptor, progesterone receptor, and HER2/neu and 
most BRCA1-mutated tumors are triple-negative (Atchley et al., 2008; Carey et al., 2006; 
Hartman et al., 2012; Millar et al., 2009; Voduc et al., 2010).  
 Immunohistochemical scores (Hscores) for Ki67, ER, CTSL, 53BP1, and VDR provided 
and semi-quantitative measurement of their expression for each tumor subtype (Goulding et al., 
1995; Pallares et al., 2009). Scores are generated by adding together 3 x % of strongly stained 
cells, 2 x % of moderately stained cells, and 1 x % of weakly stained cells, giving a possible 
range of 0 to 300. As shown in Figure, CTSL staining was both cytoplasmic and nuclear while 
53BP1 staining was only nuclear. The immunohistochemical results are summarized in Table 3-
1. Whereas cytoplasmic CTSL Hscores were similar in all tumor subtypes, nuclear CTSL 
Hscores were markedly enhanced in triple-negative tumors.  
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Proteins Molecular Type 
H score 
Kruskal-
Wallis test 
p-value Mean(SD) 
Median 
[P25, P75] 
Min-Max 
Cytoplasmic 
Cathepsin L 
Luminal A 137 (36.6) 135 [110,160] 50-205 
0.50 
Luminal B 134 (35.2) 130 [110,155] 75-230 
Erbb2 (-1) 141 (43.1) 135 [110,171] 50-230 
Triple Negative (-1) 145 (35.2) 140 [120,175] 80-200 
Nuclear 
Cathepsin L 
Luminal A 8 (18.0) 0 [0, 0] 0-90 
<.0001 
Luminal B 8 (14.9) 0 [0, 15] 0-75 
Erbb2 (-1) 9 (18.3) 0 [0, 5] 0-75 
Triple Negative (-1) 42 (44.3) 30 [0, 83] 0-125 
53BP1 
Luminal A 155 (56.5) 160 [120, 200] 0-270 
0.0002 
Luminal B 150 (45.8) 150 [120, 170] 40-280 
Erbb2 (-4) 154 (58.1) 150 [110, 200] 20-300 
Triple Negative 112 (44.4) 105 [80, 143] 0-190 
Cytoplasmic 
VDR 
Luminal A (-4) 50 (50.9) 50 [0, 90] 0-185 
0.22 
Luminal B (-4) 52 (50.8) 50 [0, 80] 0-190 
Erbb2 (-2) 53 (48.8) 50 [ 0, 95] 0-160 
Triple Negative (-3) 69 (50.6) 50 [20, 110] 0-170 
Nuclear 
VDR 
Luminal A (-4) 121 (68.2) 110 [100, 170] 0-300 
0.78 
Luminal B (-4) 125 (65.2) 130 [90, 160] 0-300 
Erbb2 (-2) 122 (73.3) 125 [95, 160] 0-300 
Triple Negative (-3) 114 (62.3) 110 [80, 150] 0-270 
Table 3-1. Immunohistochemical analysis of CTSL, 53BP1 and VDR expression in sporadic 
human breast cancers. Values are Mean and Median Hscores for nuclear and/or cytosolic CTSL, 
53BP1 and VDR per tumor molecular types. Dispersion is assessed by standard deviation (SD) and 
percentiles 25 and 75 ([P25,P75]); Min-Max denotes Minimal and Maximal Values within the tumor 
subtype. (-X) represents X missing values in antigen expression per molecular type due to insufficient 
specimen. Bolded Hscore values highlight the molecular subtype responsible for the statistical 
significant difference identified with the Kruskal-Wallis Test that compares all molecular types 
(highlighted by a bold p value in case of any significant difference among them). 
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Table 3-2. Frequency of CTSL, 53BP1 and VDR expression within 
molecular subtype relative to the median values in sporadic human 
breast cancers.  Values denote the absolute (n) and the relative (%) 
frequencies of tumors with Hscore values above (nuclear CTSL) or below 
(nuclear 53BP1 and VDR) the median Hscore values for each protein in 
the overall population of sporadic breast cancer. Bolded Hscore values 
highlight the molecular subtype responsible for the statistical significant 
difference identified with the Fisher Exact Test that compares all 
molecular types (highlighted by a bold p value in case of any significant 
difference among them). 
 
In agreement with the in vitro findings, these high nuclear CTSL Hscores correspond with lower 
53BP1 Hscores in TNBC compared to all other tumor types. Furthermore, we used the median 
nuclear Hscores for CTSL and 53BP1 of 0 and 150, respectively, as cut-off points with identical 
statistical power to confirm 
these significant differences 
in CTSL and 53BP1 
expression among tumor 
types. Again, statistically 
significant differences were 
obtained, and TNBC 
emerged from this analysis 
as a remarkably different 
tumor subtype. Table 3-2 
shows that 60% of triple-
negative tumors elicited 
Hscores of nuclear CTSL 
greater than 0, a frequency 
more than 2-fold higher 
than for any other 
molecular type 
(p=0.0013). Also, 75% of 
triple-negative tumors 
expressed 53BP1 Hscores below 150 compared to 40% of luminal A, 49% of luminal B, and 
Proteins Molecular Type n (%) 
Fisher exact 
test p-value 
Nuclear 
Cathepsin L 
> 0 
Luminal A 23 (23.2) 
0.0013 
Luminal B 22 (31.9) 
Erbb2 (-1) 12 (27.3) 
Triple Negative (-1) 21 (60.0) 
53BP1 
< 150 
Luminal A 59 (59.6) 
0.0049 
Luminal B 35 (50.7) 
Erbb2 (-4) 21 (51.2) 
Triple Negative 9 (25.0) 
Nuclear  
VDR  
< 120 
Luminal A 46 (48.4) 
0.34 
Luminal B 40 (61.5) 
Erbb2 (-4) 25 (58.1) 
Triple Negative 16 (48.5) 
80 
 
39% of HER2 tumors (p=0.0049). These data clearly show that higher expression of nuclear 
CTSL as well as lower 53BP1 is significantly more associated with TNBC than any other 
molecular subtype of breast cancer. Thus, we have identified nuclear CTSL as a novel biomarker 
for subsets of TNBC patients. Importantly, this new signature (high nuclear CTSL and low 
53BP1) could serve to stratify TNBC patients.  
Next, we analyzed breast tumors from patients with germline mutations in BRCA1 
(n=18) or BRCA2 (n=14) for levels of nuclear CTSL and 53BP1 by IHC (Table 3-3). In 
concurrence with the subsample of sporadic TNBC, tumors from patients with BRCA1 germline 
mutations elicited the same high Hscores for nuclear CTSL (p=0.95) and low Hscores for 53BP1 
(p=1). In contrast, tumors from patients with BRCA2 germline mutations had nuclear CTSL 
Hscores similar to those in all molecular subtypes of sporadic tumors and significantly lower 
than BRCA1 germline tumors. Accordingly, 53BP1 Hscores were higher in tumors from patients 
with BRCA2 germline mutations than in BRCA1-mutated tumors or all molecular subtypes of 
sporadic tumors. These results support our in vitro data for a role of CTSL in the degradation of 
53BP1 in BRCA1-deficient cells. Table 3-4 shows that a very high frequency of BRCA1-
mutated tumors exhibit high nuclear CTSL, low 53BP1, and low nuclear VDR. Importantly, 
Figure 3-2A shows a statistically significant inverse linear correlation between Hscores for 
nuclear CTSL and 53BP1 in all tumor subtypes with a positive nuclear CTSL expression. 
However, a coefficient of determination of only 6.6% indicates that there is 93.4% of the 
variability in 53BP1 Hscores that cannot be accounted for by increases in nuclear CTSL. These 
results suggest that additional factors might contribute to CTSL-mediated degradation of 53BP1 
in these tumors. Identifying these factors could help to discriminate subsets of patients in which 
this pathway is activated.  
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Table 3-3. Immunohistochemical analysis of CTSL, 53BP1 and VDR expression in tumors from 
patients with BRCA1 or BRCA2 germline mutations.  (A) Values are Mean and Median Hscores for 
nuclear and/or cytosolic CTSL, 53BP1 and VDR in tumors with BRCA1 or BRCA2 germline mutations. 
Dispersion is assessed by standard deviation (SD) and percentiles 25 and 75 ([P25,P75]); Min-Max 
denotes Minimal and Maximal Values within the tumor subtype. (-X) represents X missing values in 
antigen expression per molecular type due to insufficient specimen. Bolded Hscore values highlight the 
statistical significance of differences measured by Mann-Whitney test (M-W) between each tumor 
mutation subtype vs. the overall population of sporadic breast cancer (sporadics) or between tumors with 
BRCA1 vs. BRCA2 germline mutations (BRCA1 vs. 2). Significant differences are highlighted with bold 
p value. 
 
Proteins 
Mutation 
Type 
H score 
M-W Test 
p-value 
(vs. 
Sporadics) 
M-W Test 
p-value 
(BRCA1 vs. 
BRCA2) 
Mean (SD) 
Median 
 [P25, P75] 
Min-Max 
Cytoplasmic 
Cathepsin L 
BRCA1 
mutation (-4) 
119 (34.2) 110 [100, 138] 60-190 0.0563 
0.88 
BRCA2 
mutation (-1) 
118 (46.2) 120 [100, 120] 100-150 0.0437 
Nuclear 
Cathepsin L 
BRCA1 
mutation (-4) 
38 (45.2) 30 [15, 45] 0-180 0.0001 
0.0494 
BRCA2 
mutation (-1) 
15 (22.7) 4 [0, 15] 0-75 0.19 
53BP1 
BRCA1 
mutation (-1) 
111 (28.4) 115 [100, 125] 70-175 0.0016 
0.0001 
BRCA2 
mutation (-1) 
198 (43.6) 210 [185, 220] 110-270 0.0008 
Cytoplasmic 
VDR 
BRCA1 
mutation 
86 (38.5) 100 [50, 100] 0-150 0.0048 
0.0011 
BRCA2 
mutation (-3) 
145 (36.7) 150 [115, 165] 100-200 <.0001 
Nuclear 
VDR 
BRCA1 
mutation 
66 (52.9) 53 [27, 100] 0-180 0.0010 
0.0001 
BRCA2 
mutation (-3) 
175 (57.8) 170 [135, 193] 110-300 0.0074 
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Table 3-4. Frequency of nuclear CTSL, 53BP1 and VDR expression within BRCA1 and BRCA2-
mutated tumors. Values denote the absolute (n) and the relative (%) frequencies of tumors with 
Hscore values above (nuclear CTSL) or below (nuclear 53BP1 and VDR) the median Hscore values 
for each protein in tumors with BRCA1 or BRCA2 germline mutations.  Bolded Hscore values 
highlight the statistical significant difference measured by the bold p value from Fisher exact test 
comparing a molecular subtype with either the overall population of sporadic breast cancer (sporadics) 
or between tumors with BRCA1 vs. BRCA2 germline mutations (BRCA1 vs. 2). 
 
Previous studies in human colon cancer cells showed a correlation between expression of 
vitamin D receptor and cystatin D, an inhibitor of several cathepsins including CTSL (Alvarez-
Díaz et al., 2009), and upregulation of cystatin D by vitamin D. In addition, our in vitro data 
show that vitamin D inhibits CTSL-mediated degradation of 53BP1. Vitamin D requires a 
functional vitamin D receptor to exert its actions (Dusso, Brown, & Slatopolsky, 2005). Because 
VDR levels are reduced in several human cancers and the loss of BRCA1 causes defective VDR 
translocation to the nucleus in osteosarcoma cells (Deng et al., 2009), we hypothesized that there 
might be a threshold for nuclear VDR required to inhibit CTSL-mediated degradation of 53BP1, 
which in turn could explain the signature of tumors with high Hscores for both nuclear CTSL 
and 53BP1.  
Proteins 
Mutation 
Type 
n (%) 
Fisher exact test 
p-value  
(vs. Sporadics) 
Fisher exact test 
p-value 
 (BRCA1 vs. BRCA2) 
Nuclear 
Cathepsin L  
> 0 
BRCA1 mutation (-4) 12 (85.7) 0.0001 
0.10 
BRCA2 mutation (-1) 7 (53.8) 0.13 
53BP1  
< 150 
BRCA1 mutation (-1) 2 (11.8) 0.0019 
0.0001 
BRCA2 mutation (-1) 11 (84.6) 0.0210 
Nuclear  
VDR  
< 120 
BRCA1 mutation (-1) 3 (16.7) 0.0027 
0.0051 
BRCA2 mutation (-1) 8 (72.7) 0.35 
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Figure 3-2. Nuclear 53BP1 expression correlates inversely with nuclear CTSL
expression in sporadic human breast cancers. (A-D) Linear regression analysis
between Hscores for nuclear 53BP1 and CTSL in sporadic breast cancer samples with
Hscores for CTSL>0. Note the high variability in nuclear 53BP1 Hscores in tumors
without nuclear CTSL. The linear regression analysis of the association between
nuclear 53BP1 and CTSL depicted in panels A (Linear regression coefficient (r)= -
0.42; p=0.02; coefficient of determination ( r2)= 6.6% ) and B (r= -0.93 ; p=0.0025 ;
r2=29.2%) include Hscores from both TNBC and no TNBC tumors, while panels C (r=
-0.255 ; p=0.294; r2= 5.8 ) and D (r=-0.89; p=0.0027; r2= 80.2% ) depict TNBC only.
Note the marked increase in % of the variability in nuclear 53BP1 levels that can be
explained by changes in nuclear CTSL parameters of Panels B and D when only tumors
with nuclear VDR Hscores < 120 are included in the regression analysis.
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Our hypothesis is supported by the findings of a direct linear correlation between nuclear 
levels of VDR and 53BP1 for all 249 tumor types (Pearson Correlation r=0.238; p=0.0002). 
Analyzing the linear relationship for those tumors with nuclear VDR expression below the 
median Hscore of 120 obtained in the 249 sporadic tumors (Figure 3-2B), we find an increase in 
the slope of the linear regression of nuclear CTSL and 53BP1 Hscores (from -0.41 to -0.93) as 
well as an increased coefficient of determination (from 6.6% to 29.2%). Furthermore, when the 
correlation between 53BP1 and CTSL was examined exclusively in TNBC, the non-significant 
correlation depicted in Figure 3-2C becomes highly significant when only tumors with VDR 
less than 120 are examined (p<0.0027), as seen in Figure 3-2D, with a coefficient of 
determination of 80.2%. Indeed, the outliers in Figure 3-2C correspond to patients with VDR 
Hscores far above 120, which maintain high Hscores for nuclear 53BP1 despite Hscores for 
nuclear CTSL above 100 (Figure 3-3, top panels). Figure 3-3 (lower panels) shows the most 
common biomarker signature found in TNBC and BRCA-mutated tumors. Furthermore, average 
nuclear Hscores for VDR are lower in tumors from patients with germline BRCA1 mutations 
compared to TNBC (66 vs. 114, with p<0.009) (Tables 3-3 and 3-1), suggesting that loss of 
BRCA1 may also impair VDR translocation to the nucleus in breast cancer. The cytosolic and 
nuclear VDR Hscores in BRCA2 germline mutations depicted in Table 3-3 suggest that only 
BRCA1 mutations hinder VDR translocation to the nucleus allowing CTSL-mediated 
degradation of 53BP1. 
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In summary, this study reveals a new triple biomarker signature – levels of nuclear VDR, 
CTSL, and 53BP1- for stratification of patients with TNBC (in which BRCA1 is frequently 
somatically altered) and tumors from patients with BRCA1 germline mutations. Based on our in 
vitro data, this signature could potentially be used as a predictor of the response of these specific 
tumors to DNA damaging therapeutic strategies such as radiation, crosslinking agents, and PARP 
inhibitors. 
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Figure 3-3. Common immunohistochemical signatures in TNBC. Images of
immunohistochemical analysis results in TNBC patients. Two different signatures were
observed in these patients (as well as in patients with BRCA1 germline mutations). Top
panels show the signature of a few TNBC patients -high nuclear CTSL, 53BP1 and VDR-.
Bottom panels show the most common signature in TNBC patients –high nuclear CTSL, low
53BP1 and low nuclear VDR-.
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3.3 Vitamin D inhibits breast tumor cell growth in vivo 
 A main future goal for this study is to determine if this pathway can be exploited with 
therapeutic purposes using preclinical models. Triple-negative or BRCA1-deficient or mutated 
tumors can be implanted into mice and treated with vitamin D or cathepsin inhibitors to 
putatively reduce tumor growth by stabilizing 53BP1 levels. Vitamin D or cathepsin inhibitors 
can also be combined with radiation therapy or PARPi to increase sensitivity to the treatments. 
We have performed preliminary experiments both in culture and in mice using the 4T1 murine 
breast tumor cell line. The 4T1 cell line, isolated from a BALB/c mammary tumor, is highly 
malignant and can 
metastasize to lung, 
liver, lymph nodes, 
and brain (Aslakson 
& Miller, 1992; 
Miller, Miller, & 
Heppner, 1983). 
Importantly, 4T1 
cells are similar to a 
triple-negative breast 
cancer cell line as 
they have low levels 
of estrogen receptor, progesterone receptor, and HER2 (Kau et al., 2012) and they also have high 
cathepsin activity (Ren et al., 2011) which could lead to low endogenous 53BP1 levels. Despite 
obtaining inconclusive results regarding the effect of vitamin D treatment on 53BP1 levels by 
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Figure 3-4. Vitamin D radiosensitizes 4T1 cells. Representative
MTS assay showing proliferation of 4T1 cells after treatment with 3
modalities of vitamin D or a combination of vitamin D with ionizing
radiation. Vitamin D alone has an antiproliferative effect that is
exacerbated following irradiation indicating radiosensitization.
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western blot in these cells (data not shown), we show that vitamin D treatment in culture has an 
antiproliferative effect (Figure 3-4). When cells are treated with 3 different forms of vitamin D, 
the active 1,25-dihydroxyvitamin D3, the vitamin D precursor 25-hydroxyvitamin D, or a 
combination of both, proliferation is reduced as measured by MTS assay. Furthermore, when the 
3 different vitamin D treatments are combined with ionizing radiation, the antiproliferative effect 
is enhanced (Figure 3-4), indicating that vitamin D is inducing radiosensitization in 4T1 cells. 
 To test if vitamin D can reduce tumor growth in mice, we injected 4T1 cells into the 
mammary fat pads of BALB/c mice. The mice were treated by intraperitoneal injection of either 
vehicle or a 
combination of 
active vitamin D 
and the precursor 
and tumor growth 
was monitored by 
caliper 
measurements. 
Figure 3-5 shows 
that vitamin D 
treatment reduced 
tumor growth 
compared to mice treated with vehicle. These preliminary results provide a promising basis for 
future in vivo experiments to test if vitamin D and cathepsin inhibitors can be used to inhibit 
tumor growth as well as increase sensitivity to DNA damaging therapeutic strategies. 
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Figure 3-5. Vitamin D treatment reduces tumor growth in vivo. 4T1 cells were
injected in to mammary fat pads of BALB/c mice and tumor growth was measured
using calipers in mice that were treated or untreated with vitamin D.
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3.4 Discussion and future experiments 
 The need to identify new biomarkers for diagnosis and predictive therapeutic outcome for 
cancer is of great importance. Tumors are grouped into categories based on 
immunohistochemical staining properties that are similar between a subset of tumors; however 
there is still great heterogeneity between individual tumors. Triple-negative breast cancers are 
defined by the lack of immunohistochemical staining of estrogen receptor, progesterone receptor, 
and HER2, but there are many other molecular mechanisms that affect the growth of these 
tumors and their response to treatment (Constantinidou, Jones, & Reis-Filho, 2010). BRCA1-
related cancers are commonly triple-negative, and while these aggressive tumors have shown 
some positive response to new treatments such as PARP inhibitors, these strategies are not 
effective in all women. In this study, we identify novel biomarkers for sporadic TNBC and 
tumors from patients carrying germline mutations in BRCA1. 
The analysis of breast tumor tissue microarrays (TMA) indicates that levels of nuclear 
CTSL represent a new positive biomarker for subsets of tumors, including TNBC and tumors 
arising in association with germline mutations in BRCA-1. Similarly, we find that nuclear VDR 
levels correlate linearly with 53BP1 content in all tumor subtypes, and the lowest nuclear VDR 
levels correspond to TNBC and tumors from patients with BRCA1 germline mutations. The 
finding of the strong negative correlation between reductions in nuclear 53BP1 with increases in 
nuclear CTSL levels (80% coefficient of determination) in TNBC with nuclear VDR<120 is very 
interesting, as TNBC is associated with severe vitamin D deficiency (Peppone et al., 2011). 
Furthermore, previous studies had shown a role for VDR in the upregulation of cathepsin 
inhibitors (Alvarez-Díaz et al., 2009). Thus, it is tempting to speculate that vitamin D 
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interventions could lead to VDR-induced expression of cystatins and the attenuation of CTSL-
mediated degradation of 53BP1. Future studies testing this hypothesis might lead to new 
strategies of targeted therapy. 
The combination of low nuclear VDR or high nuclear CTSL with low 53BP1 levels 
offers great potential for the stratification of BRCA1-deficient and TNBC patients into different 
subgroups and as a predictive biomarker for the response of these patients to current therapies. In 
particular, the use of PARPi as single agents or in combination with radiation or chemotherapy is 
a leading strategy for breast cancer management, especially for HR-deficient tumors (Drew et al., 
2011; Farmer et al., 2005; Fong et al., 2009). However, a significant fraction of these cancers 
acquire resistance to PARPi. Recent studies in cell culture and mouse models demonstrated that 
loss of 53BP1 reduces the sensitivity of BRCA1-deficient cells to PARPi (Bunting et al., 2010).  
Our study suggests that BRCA1-deficient and TNBC patients that exhibit low nuclear 
VDR, high nuclear CTSL and low 53BP1 levels are likely to be proficient in HR and resistant to 
PARPi. Therefore, these patients will not benefit from this specific treatment unless levels of 
53BP1 are stabilized. For these patients, treatment with vitamin D or CTSL inhibitors to stabilize 
53BP1 levels in combination with PARPi might result in the most effective therapy. 
 Future studies in the lab will focus on determining if vitamin D or cathepsin L inhibitor 
treatment is effective in preventing tumor growth. A preliminary study has indicated that vitamin 
D is able to slow the growth of 4T1 tumors. Vitamin D is known to have an antiproliferative 
effect, and while tumor inhibition with vitamin D treatment will always be a positive outcome, it 
will be important to use CTSL inhibitors to determine if the growth reduction is due to inhibition 
of CTSL-mediated degradation of 53BP1. Cathepsin inhibition would also be supplemented with 
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either PARP inhibitor treatment or irradiation. All tumors would be collected and subjected to 
immunohistochemistry to measure levels of nuclear CTSL, VDR, and 53BP1 to determine if the 
treatment outcome coincides with our hypothesis based on the tumor tissue microarray data and 
in vitro findings. There are several mouse models of tumorigenesis that can be used. An 
orthotopic model of breast cancer in mice can be used by injecting BOGA cells into mammary 
fat pads and monitoring tumor progression following different treatments. This model would be 
difficult with MCF7 cells, however, as they do not grow well in mice. The cell line MDA-MB-
231, which is triple-negative and activates cathepsin L mediated degradation of 53BP1, would be 
a better candidate cell line for implantation into mice. Another mouse model of tumorigenesis 
that could be utilized to study the effect of vitamin D and cathepsin L inhibitors on tumor growth 
is the human-in-mouse model, in which pieces of tumors from patients are grown in mouse 
mammary fat pads (Kuperwasser et al., 2004). In this model, mammary fat pads of NOD/SCID 
mice are humanized by removing the mammary epithelium from the fat pads and replacing it 
with a mixture of irradiated and non-irradiated telomerase immortalized human mammary 
stromal fibroblasts. Two weeks later, human breast epithelial organoids and primary fibroblasts 
are injected into the humanized site to establish the tumor model. This model has already proved 
successful using triple-negative tumors (Ma et al., 2012).  
Since BRCA1 knockout mice are embryonic lethal, BRCA1 conditional knockout mice 
have been used extensively to study tumorigenesis upon loss of BRCA1 in the mouse and are 
available for purchase (Xu et al., 1999). Conditional BRCA1 knockout mice that develop tumors 
can be treated with vitamin D or cathepsin L inhibitors to evaluate their efficacy in treatment. 
Finally, a BRCA1 conditional knockout mouse could be crossed to a cathepsin L knockout 
mouse to determine if complete loss of CTSL can prevent or slow tumor formation and 
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progression. 
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CHAPTER FOUR 
 
Telomere defects and genomic stability in a premature aging 
laminopathy 
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4.1 Abstract 
 
 Expression of mutant forms of A-type lamins is associated with human diseases known 
as laminopathies, which include a variety of degenerative diseases and premature aging 
syndromes such as Hutchinson Gilford Progeria Syndrome (HGPS). In addition, changes in the 
expression of A-type lamins have been linked to tumorigenesis. Recent studies suggest that 
increased genomic instability could contribute to the pathogenesis of lamins-related diseases, 
however the cellular mechanisms that lead to these diseases remain poorly defined. Research in 
our laboratory has found that loss of A-type lamins leads to defects in telomere homeostasis and 
increased genomic instability, and implicates loss of 53BP1 as a possible mechanism behind 
these phenotypes. Here, we sought to determine if similar phenotypes are observed in a mouse 
model of progeria. We used mouse embryonic fibroblasts (MEFs) and mouse adult fibroblasts 
(MAFs) from mice that express low levels of a mutant form of A-type lamins that lacks exon 9 to 
investigate if telomere defects, heterochromatin abnormalities, and genomic instability contribute 
to progeroid syndrome pathogenesis. We find that the Δexon9Lmna mouse model exhibits 
telomere shortening and alterations of telomeric and centromeric heterochromatin, but not an 
increase in genomic instability as assessed by the frequency of chromosome and chromatid 
breaks or the extent of unrepaired DNA damage. Interestingly, the levels of 53BP1 are 
maintained in cells from these mice. These results demonstrate that different lamins mutations 
present with varying genomic instability phenotypes and suggest that 53BP1 status could be an 
important determinant for maintenance of genomic stability in lamins-related diseases. 
  
97 
 
Grotsky et al. Figure 4
C
long exp.
Lamin A
Lamin C 
β-Tubulin
W
ild
-t
yp
e
Adult 
fibroblasts
Immortal
MEFs
∆
Ex
o
n
9
Lm
n
a
H
et
er
o
zy
go
u
s
∆
Ex
o
n
9
Lm
n
a
H
o
m
o
zy
go
u
s
W
ild
-t
yp
e
A
∆
Ex
o
n
9
Lm
n
a
H
o
m
o
zy
go
u
s
Lamin A
Lamin C 
short exp.
B
W
ild
-t
yp
e
∆
Ex
9
 H
o
m
o
z
Q-FISH Genotype
# of 
metaph
# of 
telom
Average 
tel length
Tel <20Kb Tel >65Kb
Exp.1
Wild-Type MEFs 20 3486 40.36 ± 23.44 18.50% 14.37%
∆Ex9 Homoz MEFs 20 4592 22.85% 5.01%
Exp. 2
Wild-Type MEFs 30 8404 39.44 ± 20.17 14.65% 11.21%
∆Ex9 Homoz MEFs 30 7800 35.99 ± 18.45 20.21% 6.61%
Exp. 3
Wild-Type MEFs 30 8032 44.63 ± 25.13 14.59% 19.78%
∆Ex9 Homoz MEFs 30 7571 32.57 ± 17.37 25.57% 4.44%
Exp. 4
Wild-Type MAFs 30 7323 38.79 ± 16.25 12.70% 5.94%
30 6970 33.96 ± 14.60 17.62% 2.57%∆Ex9 Homoz MAFs
p
 =
  0
.0
1
8
134.05 ± 17.82
Figure 4-1. Δexon9Lmna cells have decreased
levels of A-type lamins. Western blots showing
a marked decrease in protein levels of lamin A
and lamin C in Δexon9Lmna immortal mouse
embyonic fibroblasts (MEFs) and adult
fibroblasts.
4.2 Telomere shortening in Δexon9Lmna mice 
 
 Previous studies in our laboratory have demonstrated that loss of A-type lamins leads to 
telomere shortening, defects in telomeric heterochromatin, and increased genomic instability 
(Gonzalez-Suarez et al., 2009). Furthermore, studies have shown that cells from patients with 
HGPS undergo faster telomere attrition than normal counterparts (Allsopp et al., 1992; Decker, 
Chavez, Vulto, & Lansdorp, 2009; Huang, Risques, Martin, Rabinovitch, & Oshima, 2008). 
Here, we characterized the phenotype of the mouse model of progeria, Δexon9Lmna, in order to 
compare it with other A-type lamins mutants and determine if defects in telomere biology and 
overall genomic instability could contribute to 
pathogenesis in this mouse model. 
 We first monitored the global levels of 
mutant lamin A/C proteins in both mouse 
embryonic and mouse adult fibroblasts (MEFs 
and MAFs, respectively) isolated from 
Δexon9Lmna mice. Previous studies had 
shown that the lamin A/C transcripts are not 
stable in these cells (Mounkes, Kozlov, 
Hernandez, Sullivan, & Stewart, 2003). As 
shown in Figure 4-1, cells heterozygous for 
the mutation exhibit decreased levels of A-type lamins, a defect that is greatly exacerbated in 
homozygous mutant cells. 
 Next, we determined if telomere shortening could be a factor contributing to the 
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phenotype of the Δexon9Lmna mice. Telomere length was measured in embryonic fibroblasts by 
both telomere restriction fragment analysis (TRF) and quantitative fluorescence in-situ 
hybridization (Q-FISH), and in adult fibroblasts by Q-FISH. Briefly, the TRF is conducted by 
embedding cells in agarose plugs, permeabilizing, and incubating cells with a restriction 
endonuclease to fragment genomic DNA, leaving the long telomeric tracks intact. The plugs are 
then subjected to pulsed-field gel electrophoresis and the gel is transferred to a membrane. Next, 
a southern blot is performed using a telomere specific probe to determine the distance the 
telomeres traveled in the gel. Shorter telomeres migrate further in the gel than longer telomeres, 
providing a rough estimate of telomere length in a cell population. In Q-FISH, cells are arrested 
in metaphase by treatment with colcemid and fixed in methanol-acetic acid. Metaphases are 
dropped onto slides and hybridized with a telomere specific PNA probe. Fluorescent images are 
acquired and intensity of fluorescence is measured using a computer program, TFL-Telo. The 
intensity of fluorescence is correlated with Kb of telomere tracts, providing quantitative 
measurement of telomere length in a cell population. 
Mouse embryonic fibroblasts show a faster migration of telomeres by TRF in the mutant 
cells compared to wild type, indicative of shorter telomeres (Figure 4-2A). These results were 
confirmed by three independent Q-FISH assays in Δexon9Lmna embryonic fibroblasts, which 
show an average telomere length approximately 6 Kb shorter than the telomeres of wild type 
cells (Figure 4-2B). Statistical analysis shows that these differences in telomere length between 
genotypes is significant (p=0.0181). Adult fibroblasts from Δexon9Lmna mice also exhibit 
telomere shortening (Figure 4-2B). Accordingly, a higher percentage of shorter telomeres (≤20 
Kb) and a lower percentage of longer telomeres (≥65 Kb) were observed in the mutant 
embryonic and adult fibroblasts compared to wild type.  
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These data demonstrate that low levels of expression of the Δexon9Lmna mutant form of 
A-type lamins leads to defects in the maintenance of telomere length homeostasis, supporting the 
notion that A-type lamins play a role in the control of telomere length. 
4.3 Telomere heterochromatin is altered in Δexon9Lmna fibroblasts 
 
 Telomeres have epigenetic marks, such as trimethylation of histone H3 at lysine 9 
(H3K9me3) and trimethylation of histone H4 at lysine 20 (H4K20me3), that are characteristic of 
heterochromatin (Blasco, 2007). Defects in chromatin modifying activities that are responsible 
for the maintenance of these heterochromatic marks lead to telomere elongation in the presence 
of A-type lamins (Benetti et al., 2007; García-Cao, O’Sullivan, Peters, Jenuwein, & Blasco, 
2004; Gonzalo et al., 2005). Previous studies in our laboratory demonstrated that complete loss 
of A-type lamins impacts on the epigenetic status of telomeric chromatin. Specifically, loss of A-
type lamins led to decreased levels of H4K20me3 (Gonzalez-Suarez et al., 2009). The fact that 
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A B
Figure 4-2. Telomere shortening in ∆exon9Lmna MEFs and MAFs. (A) TRF
analysis showing telomere shortening in ∆exon9Lmna MEFs. (B) Four independent Q-
FISH analyses of telomere length in wild-type and ∆exon9Lmna MEFs and MAFs are
shown, as indicated. Telomere length of at least 20 metaphases was measured. Note the
decreases in average telomere length in all mutant fibroblasts carrying the homozygous
∆exon9Lmna mutation (grey column). p value shows statistical significance (p≤0.05).
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this epigenetic defect is accompanied by telomere shortening in the LMNA null model suggests 
that A-type lamins might be necessary for telomere elongation in the context of H4K20me3 
deficiency. To determine if fibroblasts from the Δexon9Lmna exhibit alterations in the structure 
of telomeric heterochromatin, we performed chromatin immunoprecipitation (ChIP) assays with 
antibodies recognizing H3K9me3 and H4K20me3 marks (Figure 4-3A). Quanitification of at 
least three independent experiments show a 40% decrease in the levels of both heterochromatic 
marks in the Δexon9Lmna mutant cells (Figure 4-3B). These results demonstrate that different 
alterations of A-type lamins affect the status of telomeric chromatin differently. While complete 
loss of A-type lamins leads only to decreased levels of H4K20me3 at telomeres, the 
Δexon9Lmna mutant results in decreased levels of both H4K20me3 and H3K9me3. Collectively, 
these data support a role for A-type lamins in the maintenance of telomere chromatin structure. 
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Figure 4-3. Heterochromatin defects at telomeres and centromeres in ∆exon9Lmna
MEFs. (A) Chromatin immunoprecipitation (ChIP) analysis performed on wild type and
∆exon9Lmna MEFs with antibodies recognizing H3K9me3 and H4K20me3.
Immunoprecipitated DNA was dot blotted and hybridized to a telomere probe, stripped, and
rehybridized to a centromere probe (major satellite). (B) Graph showing the quantitation of
immunoprecipitated telomeric DNA after normalization to input signals in three independent
experiments for H3K9me3 and four independent experiments for H4K20me3. Bars represent
standard deviation. p value shows statistical significance (p≤0.05).
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Alterations of telomeric chromatin are often phenocopied by pericentric heterochromatin. 
Such is the case in LMNA null fibroblasts which show reduced levels of H4K20me3 at both the 
telomeric and pericentric domains (Gonzalez-Suarez et al., 2009). To determine the levels of 
H3K9me3 and H4K20me3 at pericentric domains, the immunoblots that were hybridized with a 
telomeric probe were stripped and rehybridized with a probe recognizing major satellite 
sequences. Interestingly, we found that the levels of H3K9me3 at pericentric chromatin were 
also reduced in the Δexon9Lmna mutant cells, though to a lower extent than at telomeric 
chromatin (Figure 4-3A). In contrast, the levels of H4K20me3 were maintained in the mutant 
cells at these domains. These results indicate a certain specificity with respect to epigenetic 
changes at telomeric versus pericentric chromatin in Δexon9Lmna fibroblasts. 
 Mutations in the LMNA gene and reduced expression of A-type lamins are associated 
with loss of heterochromatin from the nuclear periphery (Parnaik, 2008; Reddy, Zullo, Bertolino, 
& Singh, 2008). In mouse cells, heterochromatic domains, especially pericentric regions, are 
easily visualized by DAPI staining during interphase. In normal fibroblasts, pericentric domains 
appear as DAPI-positive clusters called chromocenters that are enriched in H3K9me3 and 
H4K20me3 marks (Probst & Almouzni, 2008). We performed immunofluorescence studies to 
test if the Δexon9Lmna mutation impacts on the structure and distribution of heterochromatin 
domains in the nucleus (Figure 4-4). We found that in mutant cells, DAPI staining is distributed 
throughout the nucleoplasm exhibiting only a few areas of compacted pericentric chromatin. 
Labeling with antibodies for H3K9me3 and H4K20me3 mirrored the DAPI distribution. The 
heterochromatic marks in mutant cells were found to be either distributed more diffusely 
throughout the nucleus or forming a few big aggregates. Overall, these studies indicate that 
expression of the Δexon9Lmna mutant protein leads to a decrease in heterochromatic marks at 
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telomeres and an overall disorganization of pericentric chromatin domains. These results support 
a role for A-type lamins in the nuclear compartmentalization of heterochromatin in mouse cells. 
 
4.4 Fibroblasts from Δexon9Lmna mice do not exhibit high levels of genomic 
instability 
 Telomere loss can lead to chromosome end-to-end fusions and other chromosomal 
aberrations that have serious detrimental effects for the integrity of the genome. LMNA null 
fibroblasts exhibit loss of telomere sequences (signal-free ends), an increased frequency in 
chromosome and chromatid breaks, and increased basal levels of unrepaired DNA damage. In 
addition, we observed decreased levels of 53BP1 in LMNA null cells (Gonzalez-Suarez et al., 
2009). We tested whether Δexon9Lmna mutant fibroblasts phenocopy any of these defects. FISH 
analysis performed with a telomere PNA probe shows that mutant embryonic fibroblasts have 
only a modest increase in telomere losses (telomere loss in 24% of metaphases versus 10% in  
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Figure 4-4. Heterochromatin disorganization in ∆exon9Lmna MEFs. Immunofluorescence
performed in wild type and ∆exon9Lmna MEFs with antibodies recognizing H3K9me3 and
H4K20me3 (green). DAPI is shown in blue. Note the diffuse and irregular distribution of
heterochromatin domains in the mutant cells.
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Figure 4-5. ∆exon9Lmna cells
maintain 53BP1 levels. Western blot
with an antibody recognizing 53BP1
shows that the levels of this protein
remain stable in ∆exon9Lmna MEFs
and MAFs.
 
wild type) (Table 4-1). Similarly, there was no evidence of increase in frequency of signal free 
ends in adult fibroblasts from Δexon9Lmna mice (Table 4-1). These studies indicate that the 
Δexon9Lmna mutation hinder telomere length maintenance while the mechanisms preventing 
terminal deletions remain largely intact. Furthermore, no 
significant increases in chromosome and chromatid 
breaks or chromosome end-to-end fusions were 
observed in the mutant cells (Table 4-1). To confirm 
that the Δexon9Lmna fibroblasts were able to maintain 
chromosome stability, we monitored the presence of 
γH2AX foci by immunofluorescence. We did not find 
any evidence of basal levels of unrepaired DNA in these 
cells (data not shown). In addition, we found that mutant 
Δexon9Lmna fibroblasts do not exhibit decreased levels of 53BP1 (Figure 4-5). Thus, in 
contrast to other mouse models of laminopathies, the Δexon9Lmna mutation does not lead to 
telomere deletions, destabilization of 53BP1, or profound genomic instability. This mutation 
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Table 4-1. ∆exon9Lmna MEFs do not have profound genomic
instability . Genomic instability was measured in wild type and
∆exon9Lmna MEFs and MAFs by counting sister telomere losses
(STL) and chromosome and chromatid breaks in metaphase
spreads.
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does lead, however, to telomere shortening and defects in telomeric and pericentric 
heterochromatin. 
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4.5 Discussion and future experiments 
 
 Although the main function of A-type lamins is to give structure and support to a cell’s 
nucleus, the wide range of diseases that are caused by mutation of the LMNA gene or changes in 
expression reveals a more complex role for these proteins in cellular processes. Much work is 
being done to elucidate how alterations of A-type lamins lead to disease. There is evidence that 
lamin-related diseases are associated with genomic instability and that improper maintenance of 
telomeres is an important factor in the pathophysiology of these diseases (Gonzalez-Suarez et al., 
2009; Liu et al., 2005; Liu & Zhou, 2008). However, the data supporting this notion remains 
scarce. Our previous studies showed that LMNA null fibroblasts exhibit defects in telomere 
structure, length and function, increased chromosome and chromatid breaks, a high degree of 
unrepaired DNA damage, and an increase in aneuploidy (Gonzalez-Suarez et al., 2009). These 
cells also exhibited destabilization of 53BP1, a key factor in the DNA damage response pathway. 
The decrease in 53BP1 provides a putative mechanism by which loss of A-type lamins promotes 
genomic instability. This study provides evidence that a mutation of LMNA that causes a 
progeroid syndrome in mice leads to different effects on chromatin structure, telomere biology, 
and genomic stability than seen in other models. 
Defects in chromatin structure 
 Previous studies in HGPS cells revealed epigenetic changes that led to alterations of 
heterochromatic marks (Shumaker et al., 2006). Mutant cells exhibited decreased levels of 
H3K27me3 from the X chromosome, a mark for facultative heterochromatin. In these cells, 
H3K9me3 is reduced and H4K20me3 is increased, both of which are marks for constitutive 
heterochromatin. In contrast, upon loss of A-type lamins, we found that the H3K9me3 mark is 
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unchanged in telomeric and pericentric domains. However, we did see a decrease in the 
H4K20me3 mark at these domains (Gonzalez-Suarez et al., 2009). In the Δexon9Lmna 
fibroblasts that were analyzed in this study, we found yet a different pattern of defects in histone 
marks. Telomeres in Δexon9Lmna cells exhibited decreased levels of both H3K9me3 and 
H4K20me3. Pericentric chromatin exhibited decreased levels of H3K9me3 while maintaining 
H4K20me3 levels. In addition, we observed that the structure of pericentric heterochromatin is 
altered in these cells. Instead of the characteristic foci-like staining areas of DAPI and 
heterochromatin marks, we observed either diffuse staining or large aggregates in the 
Δexon9Lmna fibroblasts. Overall, these studies indicate that A-type lamins play a key role in the 
maintenance of heterochromatin domains, but that different alterations of these proteins impact 
on specific chromatin-modifying activities.  
Defects in telomere biology and genomic instability 
 There is much ongoing research trying to determine the molecular mechanisms that lead 
to aging. Utilizing cells from patients with HGPS or mouse models of progeria allows studies to 
be performed under conditions where changes in the cell that lead to aging happen rapidly. There 
is growing evidence that shortening of telomeres is a major contributor to the cellular aging 
process. Cells from patients with HGPS exhibit shorter telomeres that normal counterparts. A-
type lamins play a major role in the maintenance of telomeres in these cells, as hematopoietic 
cells from HGPS patients which do not express lamins are able to maintain telomeres (Decker et 
al., 2009). Furthermore, studies performed in A-type lamin knockout mice showed that complete 
loss of A-type lamins leads to telomere shortening and an increase in complete loss of telomeres 
(Gonzalez-Suarez et al., 2009). Here, we determined whether a mouse model of progeria also 
exhibits telomere length defects. 
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 Fibroblasts from the Δexon9Lmna mice present a marked reduction of average telomere 
length but not a consistent increase in signal free ends. Maintenance of telomere length is a 
complex process that requires proper accessibility of telomerase to replicating telomeres and 
assembly of the shelterin complex at the telomere after replication to form the T-loop structure 
and prevent chromosome ends from being recognized as DNA double strand breaks. The present 
study suggests that the expression of different forms of A-type lamins affect different processes 
in the maintenance of telomere homeostasis. It is possible that the expression of Δexon9Lmna 
mutant proteins might hinder the accessibility of telomerase to the telomeres. 
 Furthermore, an overall increase in genomic instability was seen upon complete loss of 
A-type lamins. In contrast, we found no evidence of increased genomic instability in 
Δexon9Lmna fibroblasts. A striking difference between these genotypes is their ability to 
stabilize 53BP1. We found that 53BP1 levels are markedly reduced in LMNA null fibroblasts, 
however Δexon9Lmna fibroblasts are able to maintain the levels of this protein. 53BP1 is a DNA 
damage response factor that is rapidly recruited to sites of DNA double strand breaks (Schultz, 
Chehab, Malikzay, & Halazonetis, 2000). Depletion of 53BP1 revealed a role for this protein in 
p53 accumulation, regulation of cell cycle checkpoints (Manis et al., 2004; Morales et al., 2003; 
Wang, Matsuoka, Carpenter, & Elledge, 2002), and the phosphorylation of ATM substrates in 
response to ionizing radiation (DiTullio et al., 2002; Fernandez-Capetillo et al., 2002). 53BP1 
knockout mice exhibit a phenotype consistent with defects in DNA repair, such as increased 
radiosensitivity, immunodeficiency, and cancer susceptibility (Ward, Minn, van Deursen, & 
Chen, 2003). Accordingly, loss of 53BP1 hinders the processing of dysfunctional telomeres by 
NHEJ (Dimitrova, Chen, Spector, & de Lange, 2008). A role for 53BP1 in replication has also 
been described (Sengupta et al., 2004), with loss of 53BP1 decreasing cell survival and 
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enhancing chromosomal aberrations upon replication arrest (Tripathi, Nagarjuna, & Sengupta, 
2007). In summary, 53BP1 appears to function at the interface of DNA replication, 
recombination, and repair. Thus, the decrease in 53BP1 levels observed in LMNA null fibroblasts 
could explain the increased genomic instability observed in these cells. In support of this notion, 
Δexon9Lmna cells, which maintain 53BP1 levels, are able to maintain genome stability. Future 
studies should demonstrate if in fact 53BP1 deficiency is responsible for the telomere defects and 
overall genomic instability observed in some mouse models of laminopathies. 
 Experiments are ongoing in the laboratory to introduce the Δexon9Lmna mutant 
construct into LMNA null cells to determine if the DNA repair defects observed upon loss of A-
type lamins are rescued. Since 53BP1 levels are maintained in the Δexon9Lmna cells, we 
hypothesize that expression of this construct should stabilize 53BP1 levels in the LMNA null 
cells and therefore lead to chromosome end-to-end fusions of dysfunctional telomeres and rescue 
the fast phase of DNA repair as measured by comet assay. These experiments would further 
confirm that 53BP1 is responsible for the DNA repair defects in A-type lamins null cells and 
demonstrate that different expression levels of A-type lamins have different impacts on genomic 
instability and DNA repair. Experiments could be carried out to determine the effects that other 
lamins mutations have on genomic stability, DNA repair, and telomere homeostasis. Different 
mutant constructs that are associated with laminopathies in humans can be expressed in LMNA 
null cells to determine which can stabilize 53BP1 levels and rescue the defects that characterize 
these cells. These experiments would shed light into different molecular mechanisms that could 
be involved in the pathogenesis of different laminopathies and possibly reveal which domains in 
the LMNA gene are important for maintaining genomic stability. 
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5.1 General conclusions 
The work in this thesis has uncovered that a novel pathway - cathepsin L-mediated 
degradation of 53BP1- is active in two pathological scenarios: loss of BRCA1 in breast cancer 
cells, and loss of A-type lamins function. Our data indicates that this pathway could have 
diagnostic and therapeutic value in breast cancers with the poorest prognosis and in degenerative 
diseases brought on by mutations of A-type lamins, termed laminopathies. Triple negative (TN) 
and BRCA-mutated breast cancers are characterized by early onset, increased aggressiveness, are 
difficult to treat, and lead to increased metastasis compared to other breast cancers 
(Constantinidou, Jones, & Reis-Filho, 2010; Nanda, 2011). Adding to the treatment difficulties is 
the fact that many of these tumors rescue HR function and gain resistance to DNA damaging 
strategies, such as PARP inhibitors. Recent landmark studies have shown that loss of 53BP1 is 
one way in which HR is rescued in BRCA1-deficient cells, which leads to PARPi resistance 
(Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 2009). Therefore, raising the levels of 
53BP1 in BRCA1-deficient cells should render them susceptible to DNA damaging compounds. 
Until work in our laboratory identified CTSL as a novel regulator of 53BP1, very little was 
known about how levels of 53BP1 are controlled in the cell. 
Here, we demonstrate that BRCA1-deficient cancer cells activate CTSL-mediated 
degradation of 53BP1 to rescue HR defects and overcome the growth arrest that accompanies 
BRCA1 loss. We show that CTSL is responsible for the degradation of 53BP1 upon depletion of 
BRCA1, and that treatment of cells with vitamin D or cathepsin inhibitors stabilizes 53BP1 in 
BRCA1-deficient cells that bypass growth arrest. Raising 53BP1 levels in this context shifts 
DNA repair from HR to NHEJ, thereby increasing genomic instability following irradiation or 
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PARPi treatment and compromising cell proliferation. Inhibition of CTSL via vitamin D or 
specific inhibitors could represent a novel therapeutic strategy for treatment of TN and BRCA1-
mutated breast cancers. These results are summarized in Figure 5-1. Furthermore, we have 
identified a novel biomarker signature for stratification of subsets of patients with TN and 
BRCA1-mutated breast cancers. This biomarker signature consists of monitoring the nuclear 
levels of 53BP1, CTSL and VDR. We found that high nuclear CTSL correlates inversely with 
levels of 53BP1 in TNBC, especially in breast tumors exhibiting low levels of nuclear VDR. 
Overall, the proposed method will allow distinguishing tumors in which the pathway is active –
high CTSL, low 53BP1, low VDR- from those in which the pathway is inactive –high CTSL, 
high 53BP1, high VDR-. Identification of these types of tumors is expected to have great 
importance for diagnosis and customization of therapy for cancer patients. 
 Very little is known about the molecular mechanisms that lead to laminopathies. Work in 
this thesis has provided evidence that CTSL-mediated degradation of 53BP1 contributes to 
genomic instability and possibly, to the pathogenesis of some of these diseases. Previous studies 
in our laboratory had shown that complete loss A-type lamins (LMNA knockout mouse model) 
leads to telomere shortening and defects in telomere structure, and increase in overall genomic 
instability, and downregulation of 53BP1 (Gonzalez-Suarez et al., 2009). Here, we found that 
cells from the Δexon9Lmna mouse model of progeria exhibit several phenotypic differences 
from LMNA null or HGPS cells. We show that Δexon9Lmna mutation leads to telomere 
shortening and defects in heterochromatin structure, but does not increase overall genomic 
instability. Importantly, cells from these mice maintain levels of 53BP1, providing a possible 
mechanism as to how genomic stability is maintained in this model of progeria and putatively in 
other types of laminopathies. The differences in these mouse models are starting to shed some 
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light into how different alterations in A-type lamins could contribute to the pathogenesis of the 
variety of lamin-related diseases.  I will discuss in the following sections some questions that 
remain unanswered and the plans for the future of this project. 
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5.2 How is CTSL upregulated? 
Very little is known about how CTSL is regulated in the cell, so investigating how CTSL 
is upregulated upon depletion of BRCA1 is a very interesting question. BRCA1 is involved in 
genetic and epigenetic mechanisms that impact many cellular processes, including transcriptional 
regulation, maintenance of heterochromatin, regulation of DNA methylation, and miRNA 
biogenesis (Kawai & Amano, 2012; Mullan, Quinn, & Harkin, 2006; Shukla et al., 2010; Zhu et 
al., 2011). Given that in our study the activation of CTSL upon loss of BRCA1 can take upwards 
of two weeks to occur, we believe that CTSL is not likely a direct transcriptional target of 
BRCA1. Rather, we speculate that loss of BRCA1 might result in alterations in chromatin 
structure that make the CTSL gene more permissive to transcriptional activation over time. It is 
possible that changes in BRCA1 levels could have an effect on the chromatin structure of the 
CTSL gene promoter. Chromatin immunoprecipitation (ChIP) analyses can be performed on the 
CTSL promoter to determine changes in chromatin marks or to detect the binding of chromatin 
modifying factors, such as HDACs and histone methyltransferases. In addition, it would be 
important to monitor DNA methylation levels of a bona-fide CpG island identified at the CTSL 
promoter (Jean, Rousselet, & Frade, 2006). Demethylation of this region upon loss of BRCA1 
could potentially be behind the increase in CTSL expression. The effect that loss of BRCA1 has 
on CTSL promoter activity could also be measured using a luciferase reporter construct and 
promoter mutants can be made to determine which domains of the CTSL promoter are important 
for its upregulation. 
 There is evidence that Ras impacts CTSL levels. Studies by other groups have shown that 
activation of Ras leads to increased expression of CTSL as well as increased levels of nuclear 
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CTSL (Chambers, Colella, Denhardt, & Wilson, 1992; Goulet et al., 2004). Experiments are 
under way in our laboratory to determine if Ras or any of its downstream effectors are activated 
upon loss of BRCA1 in breast tumor cells and if overexpression of Ras activates CTSL-mediated 
degradation of 53BP1, which would reveal a novel role for Ras in the regulation of DNA repair 
factors and genomic stability. Experiments can also be performed to determine if inhibition of 
Ras using compounds such as farnesyltransferase inhibitors can block CTSL-mediated 
degradation of 53BP1. There is also evidence that the transcription factor STAT3 (Kreuzaler et 
al., 2011) and the tumor suppressor protein p53 (Yu, Harris, & Levine, 2006) regulate CTSL 
mRNA and protein levels, an avenue that needs to be investigated in the context of BRCA1 or 
lamins-deficiency.  
It is also unknown how loss of A-type lamins leads to transcriptional upregulation of 
CTSL. Given that A-type lamins have a role in the positioning of chromatin in the nucleus, the 
increased transcription of CTSL could be due to altered nuclear localization of the gene. 
Furthermore, since loss of BRCA1 or A-type lamins has similar effects on CTSL and 53BP1 
levels, we can identify similar mRNA expression changes in both situations. A microarray 
analysis could reveal novel regulators of CTSL, which could impact DNA repair. Since our 
experiments have shown that loss of 53BP1 is responsible for overcoming the growth arrest, an 
experiment should be carried out to determine if downregulation of 53BP1 brought on by 
depletion of A-type lamins would be sufficient to bypass the growth arrest upon loss of BRCA1. 
Furthermore, since loss of A-type lamins leads to transcriptional downregulation of BRCA1, 
which could be responsible for the activation of CTSL-mediated degradation in LMNA null cells, 
reconstitution of BRCA1 in LMNA null cells could restore the levels of 53BP1. 
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5.3 How does nuclear CTSL impact on DNA repair? 
 We have also provided evidence that depletion of CTSL increases the levels of BRCA1 
in breast cancer cells (Figure 2-6). Based on these data, we speculated that CTSL transcriptional 
upregulation upon depletion of BRCA1 would impact on BRCA1 protein stability, similarly to 
the effect of CTSL on 53BP1. To test this model, our laboratory plans to manipulate expression 
of CTSL in cells (either upregulation or depletion) and monitor the half-life of BRCA1 and 
53BP1 proteins. The results of these studies will uncover new links between proteases and DNA 
repair factors. Another intriguing question that remains unanswered is whether the nuclear form 
of CTSL is directly responsible for the degradation of 53BP1 upon BRCA1 depletion. We have 
preliminary evidence from immunohistochemistry of MCF7 cells embedded in paraffin blocks 
that nuclear CTSL is upregulated in BOGA cells (Figure 2-16), however subcellular 
fractionation experiments have been unsuccessful in locating CTSL in the nucleus. Experiments 
to locate CTSL in the nucleus will continue. We have also constructed a CTSL mutant lacking 
the signal peptide for endoplasmic reticulum targeting, which would target it to the nucleus. 
Experiments using this construct will be performed to determine if nuclear CTSL degrades 
53BP1 and BRCA1. An alternative possibility is that upregulation of CTSL leads to 53BP1 
accumulation in the cytoplasm where it is degraded by other means. It is unclear in this context 
whether the degradation of 53BP1 by CTSL is direct or indirect. To determine if the degradation 
is direct, we can perform in vitro degradation assays with purified 53BP1 and varying 
concentrations of CTSL to assess the degree of proteolysis. We can then perform mass 
spectrometry to identify sites where CTSL cleaves 53BP1, if the cleavage is direct. 
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5.4 Does CTSL regulate BRCA1 and 53BP1 during the cell cycle? 
 While levels of BRCA1 are known to fluctuate during the cell cycle, being low in G0/G1 
and peaking during G2 (Liu et al., 2010), very little is known about the levels of CTSL and 
53BP1 during the cell cycle. Since NHEJ is primarily active during G0/G1, one would likely 
speculate that levels of 53BP1 would be high during this phase of the cell cycle. Our preliminary 
results, however, indicate that 53BP1 levels are reduced in G0/G1, possibly due to degradation 
by CTSL. We found that growth arresting MCF7 cells in G0/G1 by serum deprivation leads to 
decreased levels of BRCA1, upregulation of CTSL, and downregulation of 53BP1 (Figure 2-
17). We hypothesize that the downregulation of BRCA1 during G0/G1 induces CTSL 
transcriptional upregulation, which then degrades 53BP1. Experiments are being done to 
determine the levels of these proteins during the remainder of the cell cycle to investigate if 
BRCA1 and 53BP1 mirror each other to maintain a competitive balance for proper DNA repair. 
Depleting CTSL in growth-arrested cells will allow us to determine if CTSL is responsible for 
the degradation of 53BP1. Given that CTSL may degrade BRCA1, it is possible that there is a 
feedback loop where the upregulation of CTSL in cells that have low BRCA1 further lowers the 
levels of BRCA1. Overall, these studies might reveal a functional interplay between BRCA1, 
CTSL, and 53BP1 during the cell cycle. 
5.5 Does vitamin D or CTSL inhibitor treatment reduce tumor growth in 
mouse models of tumorigenesis? 
  Future experiments will focus on determining if vitamin D or CTSL inhibitor treatment 
in conjunction with PARPi or other DNA damaging strategies is effective in reducing tumor 
growth in vivo. Based on our in vitro findings and the identification of novel biomarkers in 
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TNBC and BRCA1-mutated tumors, we expect that these kinds of tumors implanted in mice will 
respond to treatment by CTSL inhibition. Raising 53BP1 levels in BRCA1-mutated tumors or in 
TNBC tumors that have high nuclear CTSL and low 53BP1 should render the cancer cells 
susceptible to PARPi or radiation therapy. Since vitamin D has an effect on many cellular 
processes aside from inhibition of CTSL, including cell cycle regulation, it will be especially 
important to determine if specific CTSL inhibitors could reduce tumor growth. 
There are several mouse models of tumorigenesis that can be utilized to examine this. An 
orthotopic model can be used to implant BOGA cells into mammary fat pads of mice followed 
by treatment and tumor growth measurement. The human-in-mouse model could be used to 
implant pieces of triple-negative tumors into mice and determine how tumor growth is affected 
by vitamin D or CTSL inhibitor treatment. Triple-negative tumors have already been utilized in 
this mouse model (Ma et al., 2012), and would be the closest scenario possible to treatment of 
humans.  BRCA1 conditional knockout mice are also available to determine how BRCA1 
deficient tumors that arise in these mice would respond to treatment, and the mice could also be 
crossed to CTSL knockout mice to determine the effect of complete loss of CTSL on tumor 
growth. All tumors would be collected and subjected to immunohistochemistry to measure levels 
of nuclear CTSL, VDR, and 53BP1 to determine if the treatment outcome coincides with our 
hypothesis based on the tumor tissue microarray data and our in vitro findings. 
5.6 Are 53BP1 levels maintained in other laminopathies? 
 Maintenance of 53BP1 levels appears to be a mechanism to ensure genomic stability in 
the context of A-type lamins deficiency. Complete loss of A-type lamins leads to the degradation 
of 53BP1 and genomic instability, however expression of a very small amount of mutant A-type 
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lamins that do not contain exon 9 is sufficient to maintain 53BP1 levels and genomic stability. 
An important experiment to perform would be to express the Δexon9Lmna construct in LMNA 
null cells to determine if 53BP1 levels and NHEJ defects are rescued. This experiment would 
demonstrate that exon 9 of LMNA is not required for stabilization of 53BP1. We also have a 
library of mutant LMNA constructs that are associated with different laminopathies that can be 
expressed in LMNA null cells to determine which mutants stabilize 53BP1. These experiments 
could also reveal which laminopathies are characterized by genomic instability and serve to 
identify a domain in the LMNA gene that is responsible for maintaining 53BP1 levels and 
genomic stability. 
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6.1 Cell culture and cell treatments 
 All cells were maintained by standard tissue culture procedure in DMEM supplemented 
with 10% fetal bovine serum or bovine growth serum with antibiotics and antimycotics. MCF7 
and MDA-MB-231 cells were gifts from Jason Weber (Washington University). The HCC1937 
cells were gifts from Junran Zhang (Case Western Reserve University). The Δexon9Lmna mouse 
embryonic and adult fibroblasts were generated in the laboratory of Colin L. Stewart as 
described in Mounkes, Kozlov, Hernandez, Sullivan, & Stewart (2003). MCF7 cells transduced 
with sh scr or sh BRCA1 were fingerprinted and shown to correspond to parental MCF7 cells 
(data not shown). For growth arrest by serum deprivation, MCF7 cells were incubated in DMEM 
+ 0.1% FBS + antibiotics/antimycotics for 48 hours. DNA content was monitored after ethanol 
fixation and propidium iodide labeling (1 mg/ml in water). 
Cells were subjected to the following treatments: 
Vitamin D. Cells were incubated with 10
-7 M 1α,25-dihydroxyvitamin D3 (D1530, Sigma-
Aldrich) for 24-48 hours, as indicated. Aliquots of 1 nmol 1α,25-dihydroxyvitamin D3 were 
resuspended in 1 mL of BGS and diluted in DMEM to a final concentration of 10% BGS. BGS 
was the vehicle in control media.  
E-64. Cells were incubated with the broad-spectrum cathepsin inhibitor E-64 (E3132, Sigma-
Aldrich) diluted in water at a concentration of 10 µM for 24 hours.  
PARPi. Cells were treated with the PARPi EB-47 (E8405, Sigma-Aldrich) diluted in water at 
a concentration of 1.2 µg/mL for 48 hours.  
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Ionizing radiation. For determining the extent of genomic instability, cells were irradiated 
with 2 Gy and analysis of metaphase spreads was performed 24 hours post-irradiation. For 
assaying formation of IRIF, cells were irradiated with 8 Gy and fixed and processed for 
immunofluorescence 1 hour, 3 hours, or 6 hours post-irradiation as indicated. For comet assays, 
cells were irradiated with 8 Gy. 
6.2 Lentiviral transductions/Transient transfection 
Lentiviral transductions were performed as previously described (Gonzalez-Suarez et al., 
2009). Briefly, 293T cells were transfected with viral packaging (pHR’8.2ΔR) and envelope 
(pCMV-VSV-G) plasmids along with the vector containing the sh RNA of interest or sh control. 
After 48 hours, viral media was collected and used to infect target cells in one 4-6 hour infection. 
Cells were allowed to recover for 48 hours and treated with the appropriate selection drug (0.5 
mg/mL G418 or 2 µg/mL puromycin). Viral packaging and envelope plasmids were gifts from 
Sheila Stewart. Except for one shBRCA1 (sequence: TCAGTACAATTAGGTGGGCTT) that 
was constructed by Junran Zhang, the rest were purchased from the Genome Institute at 
Washington University (sh BRCA sequences #1: GAGAATCCTAGAGATACTGAA, 
#2:TATAGCTGTTGGAAGGACTAG, #3:CCCTAAGTTTACTTCTCTAAA, 
#4:GCCCACCTAATTGTACTGAAT, #5:CCCACCTAATTGTACTGAATT). The sh53BP1 
and sh CTSL constructs were purchased from Washington University. 
 HA-BRCA1 (Plasmid 14999, Addgene) transient transfections were carried out using the 
X-tremeGENE HP transfection reagent (06366236001, Roche). 
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6.3 Analysis of aberrant chromosomes 
 Cells were treated with vitamin D or E-64 for 24 hours, irradiated, and allowed to recover 
for 24 hours. Cells treated with PARPi were pre-treated with vitamin D for 24 hours followed by 
combined treatment with vitamin D and PARPi for 48 hours. Following all treatments, cells were 
arrested in mitosis by treatment with colcemid for 4 hours and metaphase spreads prepared by 
hypotonic swelling in 0.56% KCl, followed by fixation in 3:1 methanol: acetic acid. Cell 
suspensions were dropped onto slides and stained for 25 minutes in Wright-Giemsa Stain 
(9380-32, Ricca Chemical Company) and then washed in water. Slides were allowed to dry and 
were mounted using Eukitt Mounting Reagent (03989, Sigma) and analyzed at room temperature 
on a Leica DM5000 B microscope using a 100x oil objective (NA 1.30). Images were acquired 
with the Leica DFC350 FX digital camera using the Leica Application Suite Version 4.1.0 
6.4 Comet Assay 
Neutral comet assays were performed using CometSlide assay kits (Trevigen). Treated 
cells were irradiated with 8 Gy and incubated at 37ºC for different periods of time to allow DNA 
to repair (0, 30, 60, 90 min). Cells were embedded in agarose, lysed, and subjected to neutral gel 
electrophoresis. Cells were stained with ethidium bromide and visualized using a fluorescence 
microscope. Olive comet moments were calculated by multiplying the percentage of DNA in the 
tail by displacement between the means of the head and tail distributions as described in Olive, 
Banáth, & Durand (1990). The program CometScore™ Version 1.5 (TriTek) was used to 
calculate olive moments. A total of 30 comets were analyzed per sample in each experiment. 
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6.5 Immunoblotting 
Cells were lysed in RIPA buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate, 0.5% SDS) supplemented with PMSF, protease inhibitors (Sigma), 
and 20mM DTT. Protein detection was carried out using the following antibodies: BRCA1 (sc-
6954, Santa Cruz), 53BP1 (NB100-304, Novus), CTSL (sc-6500, Santa Cruz), β-Tubulin 
(T8328, Sigma), Lamin A/C (sc-20681, Santa Cruz), Actin (69100, ImmunO),  and P107 (sc-
318, Santa Cruz). 
6.6 Immunofluorescence 
For immunofluorescence of RAD51, 53BP1, H3K9me3 and H4K20me3 cells were plated 
on coverslips and fixed in 3.7% formaldehyde and 0.2% Triton-X 100 in PBS for 10 minutes at 
room temperature. Coverslips were washed and blocked for 1 hour at 37ºC in 1% BSA and 0.1% 
Triton-X 100 in PBS. Primary antibody incubation with antibodies recognizing RAD51 (1:200, 
sc-8349, Santa Cruz), 53BP1 (1:1000, NB100-304, Novus), H3K9me3 (#07-442, Upstate), or 
H3K20me3 (#07-463, Upstate) was carried out for 1 hour at 37ºC, followed by washing in PBS 
and incubation with Alexa Fluor 488 goat anti-rabbit (1:1000, A11008, Invitrogen) secondary 
antibody for 1 hour at 37ºC. After washing in PBS, coverslips were mounted using Vectashield 
with DAPI (H-1200, Vector Labs). BRCA1 immunofluorescence was performed following a 
protocol from the Fernandez-Capetillo laboratory. Briefly, cells were washed twice with PBS, 
and incubated in CSK I buffer (10 mM PIPES pH6.8, 100 mM NaCl, 300 mM sucrose, 3 mM 
MgCl2, 1 mM EGTA, and 0.5% Triton X-100) for 5 minutes. Coverslips were washed 5 times 
with cold PBS and fixed in modified STF buffer (150 mM 2-Bromo-2-nitro-1,3,-propanediol, 
108 mM diazolidinyl urea, 10 mM Na citrate, and 50 nM EDTA pH 5.7) for 30 minutes at room 
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temperature. Coverslips were then washed twice with cold PBS and permeabilized (PB buffer: 
100 mM Tris-HCl pH 7.4, 50 mM EDTA pH 8.0, and 0.5% Triton X-100) for 15 minutes at 
room temperature followed by 2 washes in PBS. Blocking, antibody staining, and mounting were 
carried out as described above, with BRCA1 antibody (sc-6954, Santa Cruz) diluted at 1:200 and 
Alexa Fluor 594 goat anti-mouse secondary antibody (A11005, Invitrogen) diluted at 1:1000. 
Microscopy and photo capture was performed at room temperature on either a Nikon 
Eclipse 90i microscope using 60x oil or 100x oil objective lenses (NA 1.4 and 1.45, respectively) 
with a Photometrics Cool Snap ES2 digital camera and MetaMorph (Version 7.1.2.0) or a Leica 
DM5000 B microscope using 63x oil or a 100x oil objective lenses (NA 1.4 and 1.3, 
respectively) with a Leica DFC350FX digital camera and the Leica Application Suite (Version 
4.1.0). 
6.7 Proliferation assays 
To quantify growth upon depletion of BRCA1, cells were plated in triplicate at 150,000 
cells/well and counted 96 hours later. Cell proliferation was measured in each cell line 4 times 
within a 14-day period. To quantify the growth of the sh 53BP1/sh BRCA1 cells, 4x10
6 
cells 
were plated in 15 cm dishes and counted every 96 hours for 20 days. In order to extrapolate 
proliferation to the respective time periods, we used the equation N=N0e
kt 
where N is the final 
number of cells, N0 is the starting number of cells, k is ln2/DT (doubling time), and t is time in 
days (Sherley, Stadler, & Stadler, 1995). For each 96 hour period we calculated the doubling 
time and used it to estimate the number of cells (N) that would result from initially plating 
150,000 (N0) and culture them for a given period of time. The doubling times for the control 
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cells remained constant throughout the time period, while the doubling times for the shBRCA1 
cells started increasing once the cells overcame the growth arrest. 
6.8 Quantitative reverse-transcription PCR 
RNA was isolated using the RNAqueous-4PCR Kit (Ambion). cDNA was generated 
from 500 ng of total RNA using TaqMan Reverse Transcription Reagents (Applied Biosystems). 
BRCA1, 53BP1, CTSL and 18S expression was determined using TaqMan Gene Expression 
Assays (Hs01556193_m1, Hs00996818_m1, Hs00377632_m1, Hs99999901_s1, respectively, 
Applied Biosystems). For the analysis, all reactions (in triplicate) were carried out by amplifying 
target gene and endogenous controls in the same plate. Relative quantitative evaluation of target 
gene was determined by comparing the cycle thresholds. 
6.9 Tissue tumor microarrays (TMA) 
A total of 249 tissue samples from patients with sporadic breast carcinoma were obtained 
at Hospital Universitari Arnau de Vilanova in Lleida, Spain from 1998 to 2012. An informed 
consent was obtained from each patient and the study was approved by the local Ethical 
Committee. The series of 249 tumor samples included formalin-fixed, paraffin-embedded blocks 
for all patients, 165 core biopsies, before the initiation of neoadjuvant treatment, and 84 surgical 
specimens, before the initiation of adjuvant treatment. Tumors were classified according to the 
expression of the following proteins: Ki67, ERα and Her2 into four molecular subtypes: Luminal 
A (n=99), Luminal B (n=69), Her2 (n=45), Triple-Negative (n=36). Luminal A tumors are 
steroid hormone receptor–positive, negative for Her2, contain less than 30% of Ki67 positive 
cells, and tend to have a good prognosis. Luminal B tumors are steroid hormone receptor–
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positive, negative for Her2, contain more than 30% Ki67 positive cells, and tend to have a worse 
prognosis than luminal A. In contrast, Her2 tumors are positive for Her2 and have been shown to 
have a poor prognosis. Triple-Negative tumors are negative for steroid hormone receptors and 
Her2 and have the worst prognosis. Moreover, tissue samples were also obtained from 18 breast 
cancers from patients carrying a BRCA1 germline mutation (Luminal A, n=1; Luminal B, n=1; 
Her2, n=2; Triple-Negative, n=15), and from 14 breast cancers from patients carrying a BRCA2 
germline mutation (Luminal A, n=6; Luminal B, n=2; Her2, n=3; Triple-Negative, n=3). These 
patients had been treated in Hospital Santa Creu I Sant Pau, Barcelona, Spain. 
A Tissue arrayer device (Beecher Instrument, MD) was used to construct the TMA. 
Briefly, all samples were histologically reviewed and representative areas were marked in the 
corresponding paraffin-blocks. Two selected cylinders (0.6 mm of largest diameter) from two 
different areas were included for each case.  
6.10 Immunohistochemical analysis 
TMA blocks were sectioned at a thickness of 3 μm, dried for 1h at 65ºC before being 
dewaxed in xylene and rehydrated through descending concentrations of ethanol, and washed 
with phosphate-buffered saline. Ki67, ERα and HER2 were used to determine molecular 
subtype. Comparative studies of CTSL, VDR, and 53BP1 expression were carried out on 
sequential serial sections. Antigen retrieval for CTSL and ERα was achieved by heat treatment at 
95ºC for 20 min in a high pH solution (DAKO). Heat-induced antigen retrieval for 53BP1 and 
Ki67 was performed in a low pH solution (DAKO). Before staining the sections, endogenous 
peroxidase was blocked. Primary antibodies and incubation times were as follows: CTSL (1:50; 
S-20, Santa Cruz Biotechnology, incubation overnight at 4ºC); 53BP1 (1:2500; NB100-304, 
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Novus Biologicals, incubation 20 minutes at room temperature); VDR (1:2000; ABCAM, 
incubation 20 min at room temperature); Ki67 (Ready-to-use; M1B, DAKO, incubation 20 
minutes at room temperature); ERα (Ready-to-use; 1D5, DAKO, incubation 20 minutes at room 
temperature), and HER2 (Herceptest Kit, DAKO). The reaction was visualized with the 
Streptovidin-Biotin Complex (DAKO) for CTSL and Envision Flex (DAKO) for 53BP1, Ki67 
and ERα. Sections were counterstained with haematoxylin. Appropriate positive and negative 
controls were also tested. 
Immunohistochemical scores provide a semiquantitative measurement of protein 
expression per tumor by taking into consideration the percentage of positive cells and the 
intensity of their staining. A histological score ranging from 0 (no immune reaction) to 300 
(maximal immunoreactivity) was obtained with the formula Histoscore (Hscore) = 1X (% light 
staining) + 2X (% moderate staining) + 3X (% strong staining). The reliability of such scores for 
the interpretation of immunohistochemical staining in TMAs has been reported (Pallares et al., 
2009). 
Her2 staining was evaluated according to a standard protocol (HercepTest; DAKO) and 
scored as 4 intensities (i.e. negative=0; weak=1+; moderate=2+; and strong=3+), considering 
negative Her2 expression for intensity values of 0, 1+ and 2+ when there was no amplification 
by FISH, and positive for intensity values of 3+ and 2+, when 2+ was amplified by FISH. For 
each marker, there were a variable number of non-assessable cases due to technical problems 
including no representative tumor sample left in the cylinders, detachment, cylinders missed 
while constructing the array, necrosis, and absence of viable tumor cells in the TMA sections. 
TMA validation methods and results are available upon request. 
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6.11 MTS assay 
 Cells were plated in quadruplicate (500 or 1000 cells/well) in 96 well plates and treated 
with vitamin D or vehicle for 48 hours prior to measurement of proliferation. On the day of 
measurement of proliferation, an appropriate volume of MTS reagent was made just before 
addition to cells. Prior to addition of MTS reagent, cell media was replaced with 100µL of pre-
warmed DMEM without phenol red. Per 1mL of PBS, 2mg of MTS powder was dissolved and 
50µL of PMS was added and mixed. 20µL of MTS reagent was added to each well and 
absorbance at 490nm was read every hour for 4 hours after addition of the reagent. 
6.12 In vivo tumor study 
 4T1 cells (gift from David Piwnica-Worms) were cultured as above. 50,000 4T1 cells per 
animal in 50µL of PBS were injected into mammary fat pads of female 6-8 week old female 
BALB/c mice. Vitamin D treatment began 6 days after tumor injection. Mice were injected i.p. 
with vehicle (PBS) or a mixture of a high dose (60ng) of the vitamin D precursor, 25-
hydroxyvitamin D, and a low dose (1ng) of the active form of vitamin D, 1,25-dihydroxyvitamin 
D3 once per week. Two other times per week mice were injected with only the active vitamin D. 
Tumor volume was measured using calipers daily. 
6.13 Chromatin immunoprecipitation (ChIP) 
 ChIP analyses were carried our as described in García-Cao, O’Sullivan, Peters, Jenuwein, 
& Blasco (2004) with several modifications. Chromatin was extracted from a total number of 
4x10
6
 MEFs and subjected to immunoprecipitation with various antibodies. To isolate 
chromatin, protein and DNA were crosslinked by treating adherent cells for 15 minutes at room 
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temperature (rt) with 1% formaldehyde in PBS. Crosslinking was terminated by adding glycine 
(final concentration of 0.125-0.150 M) for 5 minutes at rt. Cells were washed with cold PBS 
once and scraped off plates in cold PBS supplemented with PMSF and protease inhibitor 
cocktail. Cells were pelleted and lysed with lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-
HCl pH 8.0, PMSF, protease inhibitor cocktail) for 10 minutes on ice. Lysed cells were then 
sonicated using a Bioruptor sonicator (Diagenode) at 30 second intervals for 15 minutes on high 
to obtain DNA fragments between 250-1000 base pairs in length. Sonicated lysates were 
centrifuged at maximum speed for 15 minutes at rt and the chromatin containing supernatant was 
collected and the pellet was discarded. 
 Next, 200µL of lysate was transferred to a 2mL Eppendorf tube and diluted 1:10 in 
dilution buffer (1.1% Triton X-100, 0.01% SDS, 1.2mM EDTA pH 8.0, 167mM NaCl, 16.7mM 
Tris-HCl pH 8.0, PMSF, protease inhibitor cocktail) and precleared for 5 hours at 4ºC on a 
rotating platform using a 25% slurry of Protein A/G PLUS-Agarose Immunoprecipitation 
Reagent (sc-2003, Santa Cruz) was blocked with E. coli genomic DNA and BSA. Following 
preclearing, supernatant was collected by centrifugation at rt for 4 minutes at 4000rpm. Next, 
4µL of antibody of interest (anti-H3K9me3, #07-442, Upstate or anti-H4K20me3 #07-463, 
Upstate) was added to the solution at incubated on a rotating platform for 1 hour at 4º. After the 
first hour, 60µL of the protein A/G beads slurry was added and incubated on a rotating platform 
overnight at 4ºC. The solution was then centrifuged as before and the unbound fraction in the 
supernatant was saved to be used as inputs. The pelleted fraction containing the beads was 
washed with 2mL of each buffer for 4 minutes at rt on a rocking platform as follows: once in low 
salt immune complex buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 
8.0, 150mM NaCl), once in high salt immune complex buffer (0.1% SDS, 1% Triton X-100, 
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2mM EDTA, 20mM Tris-HCl pH 8.0, 500mM NaCl), once in LiCl immune complex wash 
buffer (0.25M LiCl, 1% NP-40, 1% sodium deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 
8.0), and twice in TE buffer (10mM Tris pH 8.0, 1mM EDTA). Elution of the immune 
complexes was done by adding 250µL of elution buffer (1% SDS, 50mM NaHCO3), vortexing 
slowly at rt for 15 minutes, centrifuging for 4 minutes at 4000rpm, and collecting the 
supernatant. The elution procedure was repeated again to acquire a total volume of bound 
fraction of 500µL. Crosslinks were then reversed by adding 20µL of 5M NaCl and incubating at 
65ºC overnight (inputs were included as well). 
 RNA and proteins were removed by adding 10µL of 0.5M EDTA, 20µL of 1M Tris-HCl 
pH 6.5, 2µL of RNAse (10µg/µL), and 2µL of proteinase K (20µg/µL) to each sample and 
incubating at 45ºC for 1 hour. DNA was recovered by phenol/chloroform extraction and ethanol 
precipitation. 500µL of phenol:chloroform:isoamyl alcohol 25: 24:1 was added and the solution 
was vortexed at high speed then centrifuged for 5 minutes at 10,000 rpm. The supernatant was 
collected and 500µL of chloroform:isoamyl alcohol was added and the sample was vortexed and 
centrifuged. This supernatant was transferred to a 2mL tube where we added 50µL of 5M NaCl, 
1.5mL of 100% ethanol, and 1µL of glycogen and incubated at -20ºC for 1 hour to precipitate 
DNA. The solution was centrifuged at maximum speed for 15 minutes at rt and the DNA pellet 
was washed with 70% ethanol. The pellet was air dried and resuspended in 30µL of TE buffer. 
Immunoprecipitated DNA was slot-blotted onto a Hybond N
+ 
membrane and hybridized to a 
telomeric probe (gift from T. de Lange, Rockefeller University, NY, USA) or a major satellite 
probe. The signal was quantitated using the ImageQuant software (Molecular Dynamics). Serial 
dilutions of the unbound fraction from the no antibody control were processed for inputs. We 
calculated the amount of telomeric DNA immunoprecipitated relative to the signal of the 
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corresponding inputs. The ChIP values are represented as a percentage of the total input 
telomeric DNA, therefore correcting for the difference in the number of telomere repeats. 
6.14 Terminal Restriction Fragment (TRF) analysis 
To measure telomere length we prepared cells in agarose plugs and carried out TRF 
analysis as described (Blasco et al., 1997). Cells were collected, washed in PBS, and 
resuspended in 50µL PBS and incubated at 50ºC for 5 minutes to warm them. 50µL of 2% low 
melt agarose in PBS heated to 50ºC was added to the cells and incubated for 5 minutes at 50ºC. 
The mixtures was transferred to a plug mold (#170-3713, Bio-Rad) and allowed to solidify by 
cooling for 5 minutes at rt and then for 15 minutes at 4ºC. The plugs were transferred to 1.7mL 
tubes and treated with 500µL of proteinase K (2mg/ml) and incubated at 4ºC overnight. Plugs 
were then washed in TE buffer 4 times for 1 hour each and PMSF was added to the third and 
fourth washed to inactivate the proteinase K. Samples were then stored at 4ºC in TE buffer until 
digestion. To digest, plugs were washed in water for 1 hour, then equilibrated in MboI enzyme 
buffer for 1 hour. Next the plugs were incubated in 300µL of restriction enzyme buffer 
containing 50U of MboI overnight at 37ºC. Following digestion, the plugs were washed for 30 
minutes with water and 30 minutes with 0.5X TBE buffer. Pulsed-field gel electrophoresis was 
performed using 1% low melt agarose in 0.5X TBE buffer for 23 hours at 6 V/cm
2
. Following 
electrophoresis, the gel was denatured 3 times for 30 minutes each (0.5M NaOH, 1.5M NaCl in 
water) and neutralized 3 times for 30 minutes each (0.5M Tris-HCl, 1.5M NaCl in water, pH 
adjusted to 7.0) at rt. The Whatman TurboBlotter system was used to transfer the DNA to nylon 
membrane and DNA was crosslinked to the membrane using the Stratalinker UV crosslinker. 
DNA was then hybridized to a telomeric probe. 
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6.15 Quantitative Fluorescence in situ Hybridization (Q-FISH) 
 Q-FISH was performed as described previously (Herrera, Samper, & Blasco, 1999). Cells 
were cultured in 10cm dishes to 70% confluence and colcemid was added to the media (100µL 
in 10mL media) for 4 hours to arrest cells in metaphase. Cells were trypsinized after collected 
media and PBS wash, and centrifuged. The supernatant was aspirated to leave 1mL of media and 
the cell pellet, which was gently resuspended by flicking the tube. Cells were swollen in 9mL of 
pre-heated (37ºC) hypotonic buffer (0.56% KCl) for 10 minutes at 37ºC. 3 drops of fixing 
solution (cold 3:1 methanol:acetic acid) was added to the cells and cells were centrifuged at 4ºC. 
The supernatant was aspirated to leave 1mL and cells were resuspended as above. 11mL of 
fixing solution was added dropwise while gently vortexing, followed by centrifugation, 
aspiration of the supernatant, and addition of 11 more mL of fixing solution. Cells were stored at 
least overnight at -20ºC until hybridization. 
 Cells were pelleted and resuspend in fresh fixing solution. Cells were pelleted again and 
cells were dropped onto microscope slides containing 45% acetic acid and allowed to dry 
overnight. Next, slides were washed 3 times for 5 minutes each in PBS, fixed in 4% 
formaldehyde in PBS for 10 minutes, and washed another 3 times for 5 minutes each in PBS. 
Slides were incubated in pre-heated acidified pepsin (200mL water, 200mg pepsin, 168µL 12M 
HCl) for 10 minutes at 37ºC and then washed 3 times for 5 minutes each in PBS. Slides were 
fixed again as above and washed 3 times in PBS, then the slides were dehydrated by incubating 
for 5 minutes each in 70%, 90%, and then 100% ethanol and allowed to air dry. 10µL of probe 
solution (2.5µL 1M Tris-HCl pH 7.4, 21.4µL MgCl2 buffer, 175µL deionized formamide, 5µL 
telomere probe, 12.5µL blocking reagent, 33.6µL distilled water), (MgCl2 Buffer: 25mM MgCl2, 
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9mM citric acid, 82mM Na2HPO4, adjusted pH to 7.0), (PNA telomere probe: TelC-Cy3, 
#F1002-5, Panagene), (blocking reagent: 10g Boehringer reagent in 100mL maleic acid buffer, 
pH 7.5), (maleic acid buffer: 100mM maleic acid, 150mM NaCl, pH 7.5) was added in 2 drops to 
coverslips and applied to slides. Slides were then heated on a slide warmer for exactly 3 minutes 
each at 80ºC for denaturation, then incubated in a humidified chamber in the dark for 2 hours at 
rt. Slides were then washed twice for 15 minutes while shaking at rt in buffer 1 (280mL 
formamide, 4mL 1M Tris-HCl pH 7.2, 4mL of 10% in water BSA, 112mL distilled water) and 
then 3 times for 5 minutes in buffer 2 (0.08% Tween-20 in TBS) while shaking at rt. Slides were 
dehydrated as above and mounted in Vectashield with DAPI. Fluorescent images were taken on 
a Nikon 90i upright microscope and intensity of telomere fluorescence was measured used the 
TFL-Telo program (a gift from P. Lansdorp, Vancouver, Canada) (Zijlmans et al., 1997). Images 
and telomere fluorescence values were measured from at least 50 metaphases in all cases. 
6.16 Statistical analysis 
For the in vitro experiments, a “two-tailed” student’s t-test was used to calculate 
statistical significance of the observed differences. Microsoft Excel v.2010 was used for the 
calculations. In all cases, differences were considered statistically significant when p<0.05. For 
the TMA studies, a Kruskal-Wallis test was used to test the statistical significance of the 
observed differences in CTSL, VDR and 53BP1 Hscores between molecular breast tumor 
subtypes. Tumors were partitioned according to cut-off nuclear Hscores for CTSL, 53BP1 and 
VDR selected by their median values as >0, <150 and <120, respectively.  Once cut-off points 
were applied, Fisher Exact Test was used to assess the statistical significance of the differences 
in the distribution of the two categories of CTSL, 53BP1 and VDR Hscores above or below cut 
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off points for all breast tumor types. In the analysis of BRCA1 and BRCA2 samples, we used the 
Mann-Whitney test to analyze Hscore differences between them as well as differences of each of 
them with the sample of sporadic tumors, and we used the Fisher exact test to assess differences 
in the distributions of groups defined by the same cut-off points used for the sporadic tumors. 
The subsample of TNBC was also compared with the sample of germinal BRCA1 mutated 
cancers using the same statistical tests. The Pearson correlation coefficient together with linear 
regression models assessed the statistical significance of the relationship between nuclear CTSL 
and 53BP1 Hscores. R package was used to all TMA statistical tests. Differences were 
considered significant when p<0.05.  
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